<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0810200196
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pixar
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        APIXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        250.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sudair Pharma Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sudair Pharma Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apixaban SPC Tablets contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming by blocking Factor Xa, which is an important component of blood clotting.</p><p>Apixaban SPC Tablets is used in adults:<br />- To prevent blood clots (deep vein thrombosis [DVT]) from forming after hip or kneereplacement operations. After an operation to the hip or knee you may be at a higher risk ofdeveloping blood clots in your leg veins. This can cause the legs to swell, with or without pain.If a blood clot travels from your leg to your lungs, it can block blood flow causingbreathlessness, with or without chest pain. This condition (pulmonary embolism) can be life-threatening and requires immediatemedical attention.<br />- To prevent a blood clot from forming in the heart in patients with an irregular heart beat (atrialfibrillation) and at least one additional risk factor. Blood clots may break off and travel to thebrain and lead to a stroke or to other organs and prevent normal blood flow to that organ (alsoknown as a systemic embolism). A stroke can be life-threatening and requires immediatemedical attention.</p><p>- To treat blood clots in the veins of your legs (deep vein thrombosis) and in the blood vessels ofyour lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the bloodvessels of your legs and/or lungs</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Apixaban SPC Tablets if:</strong></p><p>-You are allergic to apixaban or any of the other ingredients of this medicine (listed in section6)</p><p>-You are bleeding excessively</p><p>-You have a disease in an organ of the body that increases the risk of serious bleeding (such asan active or a recent ulcer of your stomach or bowel, recent bleeding in your brain)</p><p>-You have a liver disease which leads to increased risk of bleeding (hepatic coagulopathy)</p><p>-You are taking medicines to prevent blood clotting (e.g., warfarin, rivaroxaban, dabigatran orheparin), except when changing anticoagulant treatment while having a venous or arterial lineand you get heparin through this line to keep it open or if a tube is inserted into your bloodvessel (catheter ablation) to treat an irregular heartbeat (arrhythmia).</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before you take this medicine if you have any of the following:<br />- An increased risk of bleeding, such as:<br />1.bleeding disorders, including conditions resulting in reduced platelet activity<br />2.very high blood pressure, not controlled by medical treatment<br />3.you are older than 75 years<br />4.you weigh 60 kg or less<br />- A severe kidney disease or if you are on dialysis<br />- A liver problem or a history of liver problems</p><p>Apixaban SPC Tablets will be used with caution in patients with signs of altered liver function.<br />-Had a tube (catheter) or an injection into your spinal column (for anaesthesia or pain reduction),your doctor will tell you to take Apixaban SPC Tablets 5 hours or more after catheter removal-If you have a prosthetic heart valve-If your doctor determines that your blood pressure is unstable or another treatment orsurgical procedure to remove the blood clot from your lungs is planned-- If you know that you have a disease called antiphospholipid syndrome (a disorder of theimmune system that causes an increased risk of blood clots), tell your doctor who will decide ifthe treatment may need to be changed.-If you need to have surgery or a procedure which may cause bleeding, your doctor might askyou to temporarily stop taking this medicine for a short while. If you are not sure whether aprocedure may cause bleeding ask your doctor.</p><p><strong>Children and adolescents</strong></p><p>Apixaban SPC Tablets is not recommended in children and adolescents under 18 years of age</p><p><strong>Other medicines and Apixaban SPC Tablets</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.<br />Some medicines may increase the effects of Apixaban SPC Tablets and some may decrease its effects. Your doctor will decide, if you should be treated with Apixaban SPC Tablets when taking these medicines and how closely you should be monitored.<br />The following medicines may increase the effects of Apixaban SPC Tablets and increase the chance for unwanted bleeding:<br />- Some medicines for fungal infections (e.g., ketoconazole, etc.)<br />- Some antiviral medicines for HIV / AIDS (e.g., ritonavir)<br />- Other medicines that are used to reduce blood clotting (e.g., enoxaparin, etc.)<br />- Anti-inflammatory or pain medicines (e.g., acetylsalicylic acid or naproxen). Especially, ifyou are older than 75 years and are taking acetylsalicylic acid, you may have an increasedchance of bleeding.<br />- Medicines for high blood pressure or heart problems (e.g., diltiazem)<br />- Antidepressant medicines called selective serotonin re-uptake inhibitors orserotonin norepinephrine re-uptake inhibitors</p><p>The following medicines may reduce the ability of Apixaban SPC Tablets to help prevent blood clots from forming:<br />- Medicines to prevent epilepsy or seizures (e.g., phenytoin, etc.)<br />- St John&rsquo;s Wort (a herbal supplement used for depression)<br />- Medicines to treat tuberculosis or other infections (e.g., rifampicin)</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before taking this medicine.<br />The effects of Apixaban SPC Tablets on pregnancy and the unborn child are not known. You should not take Apixaban SPC Tablets if you are pregnant. Contact your doctor immediately if you become pregnant while taking Apixaban SPC Tablets.<br />It is not known if Apixaban Tablets passes into human breast milk. Ask your doctor, pharmacist or nurse for advice before taking this medicine while breast-feeding. They will advise you to either stop<br />breastfeeding or to stop/not start taking Apixaban SPC Tablets</p><p><strong>Driving and using machines</strong></p><p>Apixaban SPC Tablets has not been shown to impair your ability to drive or use machines</p><p><strong>Apixaban SPC Tablets contains lactose (a type of sugar).</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure</p><p><strong>Dose</strong></p><p>Swallow the tablet with a drink of water. Apixaban SPC Tablets can be taken with or without food. Try to take the tablets at the same times every day to have the best treatment effect.<br />If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Apixaban SPC Tablets. The tablet may be crushed and mixed with water, or 5% dextrose in water, or apple juice or apple puree, immediately before you take it.</p><p><strong>Instructions for crushing:</strong></p><p>&bull;Crush the tablets with a pestle and mortar.<br />&bull;Transfer all the powder carefully into a suitable container then mix the powder with alittle e.g., 30 mL (2 tablespoons), water or one of the other liquids mentioned above tomake a mixture.<br />&bull;Swallow the mixture.<br />&bull;Rinse the pestle and mortar you used for crushing the tablet and the container, with alittle water or one of the other liquids (e.g., 30 mL), and swallow the rinse.<br />If necessary, your doctor may also give you the crushed Apixaban SPC Tablets tablet mixed in 60 mL of water or 5% dextrose in water, through a nasogastric tube.</p><p>Take Apixaban SPC Tablets as recommended for the following: To prevent blood clots from forming after hip or knee replacement operations. The recommended dose is one tablet of Apixaban SPC Tablets 2.5 mg twice a day. For example, one in the morning and one in the evening.<br />You should take the first tablet 12 to 24 hours after your operation.<br />If you have had a major hip operation you will usually take the tablets for 32 to38 days If you have had a major knee operation you will usually take the tablets for 10 to 14 days<br />To prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.</p><p>The recommended dose is one tablet of Apixaban SPC Tablets 5 mg twice a day. The recommended dose is one tablet of Apixaban SPC Tablets 2.5 mg twice a dayif:<br />- You have severely reduced kidney function<br />- Two or more of the following apply to you:<br />1.Your blood test results suggest poor kidney function (value of serum creatinine is 1.5mg/dL (133 micromole/L) or greater)<br />2.You are 80 years old or older<br />3.Your weight is 60 kg or lower.<br />The recommended dose is one tablet twice a day, for example, one in the morning and one in the evening. Your doctor will decide how long you must continue treatment for.<br />To treat blood clots in the veins of your legs and blood clots in the blood vessels of your lungs<br />The recommended dose is two tablets of Apixaban SPC Tablets 5 mg twice a day for the first 7 days, for example, two in the morning and two in the evening.<br />After 7 days the recommended dose is one tablet of Apixaban SPC Tablets 5 mg twice a day, for example, one in the morning and one in the evening</p><p>For preventing blood clots from re-occurring following completion of 6 months of treatment<br />The recommended dose is one tablet of Apixaban SPC Tablets 2.5 mg twice a day for example, onein the morning and one in the evening.<br />Your doctor will decide how long you must continue treatment for</p><p><strong>Your doctor might change your anticoagulant treatment as follows:</strong></p><p>- Changing from Apixaban SPC Tablets to anticoagulant medicines<br />Stop taking Apixaban SPC Tablets. Start treatment with the anticoagulant medicines (for example heparin) at the time you would have taken the next tablet.<br />- Changing from anticoagulant medicines to Apixaban SPC Tablets<br />Stop taking the anticoagulant medicines. Start treatment with Apixaban Tablets at the time you would have had the next dose of anticoagulant medicine, then continue as normal.<br />- Changing from treatment with anticoagulant containing vitamin K antagonist (e.g., warfarin)to Apixaban SPC Tablets<br />Stop taking the medicine containing a vitamin K antagonist. Your doctor needs to do blood- measurements and instruct you when to start taking Apixaban SPC Tablets.<br />- Changing from Apixaban SPC Tablets to anticoagulant treatment containing vitamin K<br />antagonist (e.g., warfarin).</p><p>If your doctor tells you that you have to start taking the medicine containing a vitamin K antagonist, continue to take Apixaban SPC Tablets for at least 2 days after your first dose of the medicine containing a vitamin K antagonist. Your doctor needs to do blood-measurements and instruct you when to stop taking Apixaban SPC Tablets</p><p><strong>Patients undergoing cardioversion</strong></p><p>&nbsp;If your abnormal heartbeat needs to be restored to normal by a procedure called cardioversion, take Apixaban SPC Tablets at the times your doctor tells you, to prevent blood clots in blood vessels in your brain and other blood vessels in your body.</p><p>If you take more Apixaban SPC Tablets than you should&nbsp; Tell your doctor immediately if you have taken more than the prescribed dose of Apixaban SPC Tablets. Take the medicine pack with you, even if there are no tablets left. If you take more Apixaban SPC Tablets than recommended, you may have an increased risk of bleeding. If bleeding occurs, surgery Comma blood transfusions may be required or other treatments that may reverse factor Xa activity.</p><p>If you forget to take Apexipan SPC tablet:<br />-Take the dose as soon as you remeber and:</p><p>-take the next dose of Apixaban SPC Tablets at the usualtime</p><p>-then continue as normal</p><p>If you are not sure what to do or have missed more than one dose, ask your doctor, pharmacist or nurse.</p><p><strong>If you stop taking Apixaban SPC Tablets</strong><br />Do not stop taking Apixaban SPC Tablets without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early.<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Apixaban SPC Tablets can be given for three different medical conditions. The known side effects and how frequently they occur for each of these medical conditions may differ and are listed separately below.<br />For these conditions, the most common general side effect of Apixaban SPC Tablets is bleeding which may be potentially life threatening and require immediate medical attention.<br />The following side effects are known if you take Apixaban SPC Tablets to prevent blood clots from forming after hip or knee replacement operations.</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>- Anemia which may cause tiredness or paleness<br />- Bleeding including:<br />- bruising and swelling<br />- Nausea (feeling sick)</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>- Reduced number of platelets in your blood (which can affect clotting)<br />- Bleeding: occurring after your operation including bruising andswelling, blood or liquid leaking from the surgical wound/incision(wound secretion) or injection site, in your stomach, bowel orbright/red blood in the stools, blood in the urin, from your nose &amp;from the vagina<br />- Low blood pressure which may make you feel faint or have a quickened heartbeat<br />- Blood tests may show: abnormal liver function, an increase in some liver enzymes, anincrease in bilirubin, a breakdown product of red blood cells, which can cause yellowing ofthe skin and eyes.<br />- Itching</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>- Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongueand/or throat and difficulty breathing. Contact your doctor immediately if you experience any ofthese symptoms.<br />- Bleeding: into a muscle, in your eyes, from your gums and blood in your spit when coughing. &amp;from your rectum</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>-Bleeding: in your brain or in your spinal column, in your lungs or your throat comma in your mouth, into your abdomen or space behind your abdominal cavity, from a haemorrhoid &amp; tests showing blood in the stools or in the urine</p><p>-Skin rash</p><p>The following side effects are known if you take Apixaban SPC Tablets to prevent a blood clot from forming in the heart in patients with an irregular heart beat and at least one additional risk factor.</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>-Bleeding including: in your eyes, in your stomach or bowel, from your rectum, blood in the urinecomma from your nose, from your gums &amp; bruising and swelling.</p><p>-Anemia which may cause tiredness or paleness</p><p>-Low blood pressure which may make you feel faint or have a quickened heartbeat-Nausea (feeling sick)</p><p>-Blood tests may show: an increase in gamma-glutamyl transferase (GGT)</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>-Bleeding: in your brain or in your spinal column, in your mouth or blood in your spit whencoughing, into your abdomen, or from the vagina, bright/red blood in the stools, bleedingoccurring after your operation including bruising and swelling, blood or liquid leaking from thesurgical wound/incision (wound secretion) or injection site, from a hemorrhoid &amp; tests showingblood in the stools or in the urine.</p><p>-Reduced number of platelets in your blood (which can affect clotting)</p><p>-Blood tests may show: abnormal liver function, an increase in some liver enzymes, anincrease in bilirubin, a breakdown product of red blood cells, which can cause yellowing of theskin and eyes.</p><p>-Skin rash</p><p>-Itching</p><p>-Hair loss</p><p>-Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongueand/or throat and difficulty breathing. Contact your doctor immediately if you experience any ofthese symptoms.</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong><br />- Bleeding: in your lungs or your throat, into the space behind your abdominal cavity &amp; into amuscle</p><p>The following side effects are known if you take Apixaban SPC Tablets to treat or prevent re-occurrence of blood clots in the veins of your legs and blood clots in the blood vessels of your lungs.</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>- Bleeding including: from your nose, from your gums, blood in the urine, bruising and swelling, inyour stomach, your bowel, from your rectum, in your mouth &amp; from the vagina.<br />- Anemia which may cause tiredness or paleness<br />- Reduced number of platelets in your blood (which can affect clotting)<br />- Nausea (feeling sick)<br />- Skin rash<br />- Blood tests may show: an increase in gamma-glutamyl transferase (GGT) or alanineaminotransferase (ALT)</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>-Low blood pressure which may make you feel faint or have a quickened heartbeat</p><p>-Bleeding: in your eyes, in your mouth or blood in your spit when coughing, bright/red blood in the stools, tests showing blood in the stools or in the urine, bleeding occurring after your operation including bruising and swelling, blood or liquid leaking from the surgical wound/incision (wound secretion) or injection site, from a hemorrhoid a comma and into a muscle</p><p>-Itching</p><p>-Hair loss</p><p>-Allergic reactions (hypersensitivity) which may cause: swelling of the face, lips, mouth, tongue and/or<br />throat and difficulty breathing. Contact your doctor immediately if you experience any of these symptoms.</p><p>-Blood tests may show: abnormal liver function, an increase in some liver enzymes, an increase inbilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes.</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>Bleeding: in your brain or in your spinal column, in your lungs</p><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><p>Bleeding: into your abdomen or the space behind your abdominal cavity</p><p><strong>Reporting of side effects </strong></p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via submitting completed forms to: npc.drug@sfda.gov.sa. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.</p><p>Do not store above 30˚C.Protect from light and moisture.</p><p>The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste.</p><p>Ask your pharmacist how to throw away medicines you no longer use.</p><p>These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is apixaban.<br />Each film coated tablet contains 2.5 mg of apixaban.</p><p>The other ingredients are:<br />-Tablet core: Lactose Monohydrate, Microcrystalline cellulose PH 101, Croscarmellose sodium,Sodium lauryl sulfate, Purified water, Magnesiumstearate<br />-Film coat: Opadry II Yellow32K520116</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Yellow, round, biconvex, film coated tablets , debossed with "M" on one side and "2.5" on other side.
10's PVC/PVdC-Alu Blister pack
60's, 1000's, Simulated bulk pack of 200's count Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorization holder by:</p><p>Sudair Pharma Company<br />King Fahd Road &ndash; Alrahmania<br />Building 911<br />Phone: +966114668193<br />Fax: +966114668195<br />www.sudairpharma.com</p><p>&nbsp;</p><p>Manufacturer by:<br />MSN LABORATORIES PRIVATE LIMITED<br />Formulations Division, Unit-II, Survey Nos. 1277, 1319 to 1324, Nandigama (Village &amp; Mandal),<br />Rangareddy District, Telangana 509228, India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                01/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي أبیكسابان اس بي سي أقراص على المادة الفعّالة أبیكسابان وینتمي إلى مجموعة من الأدویة تُسمى مضادات التجلط (مضادات تخثر الدم) .<br />وھو عنصر ھام من عناصر تجلُّط الدَّم . ،(Xa) یُساعد ھذا الدواء على منع تكوُّن الجلطات الدمویة عن طریق حصر العامل العاشر الفعال</p><p><strong>یُستخدَم أبیكسابان اس بي سي في المرضى من البالغین في الحالات التالیة :</strong><br />&bull;&nbsp;لمنع تكوُّن الجلطات الدمویة ((التخثُّر الوریدي العمی ق &quot;DVT&quot;) بعد إجراء جراحات استبدال مفصل الحوض أو الركبة. قد تكون أكثر عرضةالتخثُّر الوریدي العميق لخطر الإصابة بجلطات دمویة في أوردة الساق بعد إجراء جراحة بمفصل الحوض أو الركبة. یمكن أن یُسبب ذلك تورم الساقین مع الشعور بألم أو بدون ألم. إذا انتقل التجلط الدموي من لا ساق إلى لا رئ ة، فقد یمنع ذلك تدفق الدم مما یسبب ضیق مع الشعور بألم أو بدون ألم. قد تكون ھذه الحالة التي تُعرف بالانصمام الرئوي &quot;انسداد الشریان الرئوي&quot; مُھدِدة للحیاة وتستدعي العنایة الطبیة الفوریة.<br />&bull; لمنع تكوُّن جلطة دمویة في القلب لدي المرضى الذین یعُانون من عدم انتظام ضربات القلب (الرجفان الأذیني) ووجود عامل خطر إضافي واحد<br />على الأقل. قد تنفصل الجلطات الدمویة وتنتقل إلى المخ مما یؤدي إلى الإصابة بسكتة دماغیة أو قد تنتقل إلى الأعضاء الأخرى وتمنع التدفق<br />الطبیعي للدم إلى ھذه الأعضاء (یُعرَف ذلك أ یضًا باسم الانصمام الجھازي). قد تكون السكتة الدماغیة مُھدِّدة للحیاة وتستدعي العنایة الطبیة<br />الفوریة .<br />&bull; لعلاج الجلطات الدمویة في أوردة الساق (التخثُّر الوریدي العمیق) وفي الأوعیة الدمویة بالرئ ة (الانصمام الرئوي)، ولمنع تكرار حدوث<br />الجلطات الدمویة في الأوعیة الدموی ة ب الساق و/أو بالرئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول أبیكسابان اس بي سي أقراص في الحالات الآتیة :</strong></p><p>&bull; إذا كنت تعُاني من حساسیة تجاه مادة الأبیكسابان أو أي مكون من المكونات الأخرى التي تدخ ل في تركیب ھذا الدَّواء (المدرجة في اقل سم رقم 6).<br />&bull; إذا كنت تُعاني من النزیف بشكل مفرط .<br />&bull; إذا كنت تعُاني من مرض بأحد أعضاء الجسم یُؤدي إلى ارتفاع نسبة خطورة حدوث نزیف حاد (مثل قرحة نشطة أو حدیثة في المعدة أو الأمعاء أو نزیف في المخ أُصِبت بھ مؤخرًا).<br />&bull; إذا كنت تُعاني من مرض بالكبد یُؤدي إلى ارتفاع نسبة خطورة الإصابة بنزیف (تجلط الدَّم الكب دي).<br />&bull; إذا كنت تتناول أدویة لمنع تجلط الدم (على سبیل المثال؛ وارفارین أو ریفاروكسابان أو دابیجاتران أو ھیبارین)، ما عدا في حالة تغی یر العلاج المضاد للتجلط أو عندما یكون مثبت لك قسطرة رقیقة داخل خط وریدي أو شریاني ویتم إعطاؤك ھیبارین من خلالھا لإبقائھ مفتوحًا (منع انسداد الخط الوریدي أو الشریاني) أو إذا تم إدخال أنبوب في احد اوعیتك الدمویة (استئصال القسطرة) لعلاج عدم انتظام ضربات القلب (عدم انتظام<br />ضربات القلب)</p><p><strong>تحذیرات واحتیاطا ت</strong></p><p>تحدث إلى الطبیب المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابع (ة) لحالتك قبل تناوُل ھذا الدواء إذا كنت تُعاني من الحالات التالیة :<br />&bull; إذا كنت تعاني من خطورة مت زایدة لحدوث نزیف، وتشمل ما يلي&nbsp;:<br />- اضطرابات نزفیة، بما في ذلك الحالات التي تُؤدي إلى انخفاض نشاط الصفائح الدَّمویة .<br />- ارتفاع ضغط الدَّم الشدید، الذي لا یمكن التَّحكم بھ من خلال العلاج الطبي.<br />- إذا كان عمرك یتجاوز 75 عامًا.<br />- إذا كان وزنك 60 كجم أو أقل.<br />&bull; إذا كن ت تعاني من مرض حاد بالكُلى أو إذا كنت تخضع لغسیل الكُلى .<br />&bull; إذا كنت تعاني من مشكلة بالكبد أو لدیك تاریخ مرضي من مشاكل الكبد.</p><p>يستخدم أبیكسابان اس بي سي أقراص بحذر في المرضى الذین یعانون من علامات تغیُّر وظائف الكبد .<br />&bull; إذا كان لدیك أنبوب مثبت (قسطرة) أو خضعت لحقن في العمود الفقري (للتخدیر أو لتخفیف الأل م)، فسیخبرك الطبیب المعالج لك بتناوُل<br />أبیكسابان اس بي سي أقراص بعد 5 ساعات أو أكثر من إزالة القسطرة .<br />&bull; إذا كنت قد خضعت لعملیة زرع صمام قلب اصطناعي .<br />&bull; إذا أقر الطبیب المعالج لك بأن ضغط دمك غیر مستقر أو أنھ من المخطط تلقي علاج أو إجراء جراحي آخر لإزالة الجلطة الدمویة من الرئ ة.<br />&bull; إذا كنت تعرف أن لدیك مرضًا یسمى متلازمة الفوسفولیبید (اضطراب في الجھاز المناعي الذي یسبب زیادة خطر جلطات الدم) ، أخبر طبیبك الذي سیقرر ما إذا كان العلاج قد یحتاج إلى تغییر.<br />&bull; إذا احتجت إلى الخضوع إلى جراحة أو إجراء قد یسبب لك نزیفًا، فقد یطل ب الطبیب المعالج لك التوقف مؤقتًا عن تناوُل ھذا الدواء لفترة قصیرة.<br />استشر الطبیب المعالج لك إذا لم تكن متأكدًا مما إذا كان الإجراء قد یُسبب نزیفًا أم لا.</p><p>المرضى من الأطفال والمراھقین</p><p>لا یُوصى باستخدام أبیكسابان اس بي سي أقراص في المرضي من الأطفال والمراھقین الذین تقل أعمارھم عن 18 عامًا.</p><p>استخدام أدویة أخرى مع أبیكسابان اس بي س ي أقراص</p><p>یُرجى إبلاغ الطبیب المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابعة(ة) لحالتك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أیَّة أدویة أخرى .<br />قد تزید بعض الأدویة من تأثیر أبیكسابان اس بي سي أقراص وقد تقلل بعض الأدویة الاخرى من تأثیره.<br />سیقرر الطبیب المعالج لك ما إذا كان یجب علاجك ب أبیكسابان اس بي سي أقراص أثناء تناوُل ھذه الأدویة أم لا وإلى أي مدى یجب متابعة حالتك.<br />قد تز ید الأدویة التَّالیة من تأثیرات أبیكسابان اس بي سي أقراص وزیادة نسبة حدوث نزیف غیر مرغوب بھ :<br />&bull; بعض الأدویة التي علاج الأمراض الفطریة (مثل كیتوكونازول... وما إلى غیر ذلك).<br />&bull; بعض الأدویة المضادة للفی روسات مثل أدویة علاج فیروس نقص المناعة البشري/الإیدز (مثل ریتونافیر).<br />&bull; بعض الأدویة التي تُستخدَم للحد من تجلط الدَّم (مثل إنُوكسابارین... وما إلى غیر ذلك).<br />&bull; الأدویة المضادة للالتھابات أو الألم (مثل حمض أسیتیل سالیس یلیك أو نابْروكْسین). خاصةً، إذا كان عمرك یتجاوز 75 عامًا وتتناول حمض أسیتیل سالیسیلیك، فقد یؤدي ذلك إلى ارتفاع نسبة حدوث نزیف .<br />&bull; الأدویة الت تستخدم لعلاج ارتفاع ضغط الدَّم أو مشاكل القلب (مثل دیلتیازیم).<br />أو مثبطات&nbsp;إعادة امتصاص السیروتونین (SSRIs) &bull; الأدویة المضادة للاكتئاب التي تُعرف باسم مثبطات إعادة امتصاص السیروتونین الانتقائیة والنورإبینفرین.</p><p><strong>قد تقلل الأدویة ال تَّالیة من قدرة أبیكسابان اس بي سي أقراص على المساعدة في منع تكوُّن جلطات دمویة:</strong></p><p>&bull; الأدویة التي تمنع حدوث نوبات صرع أو نوبات تشنجیة (مثل فینیتوین... وما إلى غیر ذلك).<br />&bull; نبتة سانت جونز ( دواء عشبي یُستخدَم لعلاج الاكتئاب) .<br />&bull; الأدویة التي تعالج السل أو أنواع العدوى الأخرى (مثل ریفامبیسین).</p><p><strong>الحمل والرضاعة الطبیعية</strong></p><p>إذا كنتِ حاملًا أو تمارسین الرضاعة الطبیعیة أو تعتقدین أنكِ حام لاً أو تخططین للحمل، فاستشیري الطبیب المعالج لكِ أو الصیدلي الخاص بكِ أو الممرض (ة) المتابع (ة) لحالتك قبل تناوُل ھذا الدَّواء.<br />حیث أن آثار أبیكسابان اس بي سي أقراص على الحمل والجنین غیر معروفة .<br />یحظر علیكِ تناول أبیكسابان اس بي سي أقراص إذا كنتِ حاملاً .<br />اتصلي بالطبیب المعالج لكِ على الفور، إذا أصبحتِ حاملًا أثناء تناوُل بأ یكسابان اس بي سي أقراص.<br />من غیر المعروف ما إذا كان أبیكسابان اس بي سي أقراص یُفرز في لبن الأم أم لا. استشیري الطبیب المعالج لكِ أو الصیدلي الخاص بكِ أو الممرض(ة)<br />المتابع (ة) لحالتك قبل تناوُل ھذا الدَّواء أثناء الرضاعة الطبیعیة.<br />حیث انھم سوف یقدمون لكِ النصیحة إما بإیقاف الرضاعة الطبیعیة أو التَّوقف عن تناوُل أبیكسابان اس بي سي أقراص أو عدم البدء في تناوله.</p><p><strong>القیادة واستخدام الآلات</strong></p><p>لم یظھر أبیكسابان اس بي سي أقراص أیة آثار من شأنھا أن تضعف قدرتك على القیادة واستخدام الآلات.</p><p><strong>یحتوي أبیكسابان اس بي سي أقراص على اللاكتوز (أحد أنواع السكر) .</strong></p><p>إذا كان الطبیب المعالج لك قد أخبرك بأنك لا تتحمل بعض أنواع السكریات، فاتصل بھ قبل تناول ھذا المنتج الدوائي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا ھذا الدَّواء تمامًا كما أخبرك الطب یب المعالج لك أو الصیدلي الخاص بك. یرُجى مراجعة الطبیب المعالج لكِ أو الصیدلي الخاص بكِ أو الممرض (ة) المتابع (ة) لحالتك إذا لم تكن متأكد ا من كیفیة التَّناوُل</p><p><strong>الجرعة</strong><br />ابتلع القرص مع كوب من الماء.<br />یمكن تناول أبیكسابان اس بي سي أقراص مع الطعام أو بدونھ. حاول أن تتناول الأقراص في نفس الوقت من كل یوم للحصول على أفضل فعّالیة علاجیة .<br />إذا كنت تواجھ صعوبة في ابتلاع القرص كاملًا، فتحدث إلى الطبیب المعالج لك بشأن الطرق الأخرى لتناول أبیكسابان اس بي س ي أقراص. یمكن أن یتم تكسیر القرص وخلطھ مع الماء أو مع محلول دكستروز 5٪ أو مع عصیر التفاح أو ھریس التفاح مباشرًة قبل تناوله</p><p><strong>تعلیمات تكسیر القرص وتفتيته&nbsp;:</strong><br />&rsquo; قم بتكسیر القرص وتفتیھ باستخدام ھاوَنٌ اومِدقََّ .<br />&rsquo; قم نب قل المسحوق كاملًا بعنایة في إناء مناسب، ثم اخلط المسحوق، على سبیل المثال، قلیل من الماء ( 30 مل (ملعقتان كبیرتان) أو أحد السوائل الأخرى المذكورة أعلاه لت ح ضیر الخلیط .<br />&rsquo; ثم قم بابتلاع الخلیط.<br />&rsquo; قم بشطف الھاون اوالمدق المستخدمین في سحق القرص إلى جانب الإناء المستخدم أیضًا بالقلیل من الماء (على سبیل المثال 30 مل من الماء)<br />&rsquo; قد یقوم الطبیب المعالج لك، إذا لزم الأمر، بإعطائك قرص من أبیكسابان اس بي سي أقراص مخلوطً ا في 60 مل من المیاه أو مع محلول دكستروز 5٪ ، بواسطة أنبوب أنفي مِعدي.</p><p><strong>تناول أبیكسابان اس بي سي أقراص على النحو الموصى في الحالات التالیة :</strong><br />في حالة الاستخدام لمنع تكوُّن الجلطات الدمویة بعد إ جراء جراحات استبدال مفصل الحوض أو الركبة.<br />الجرعة الموصى بھا ھي قرص واحد من أبیكسابان اس بي سي أقراص 2.5 مجم مرتان یومیًا. على سبیل المثال، قرص واحد في الصباح وآخر في المساء.<br />یجب أن تتناول القرص الأول بعد 12 إلى 24 ساعة من وقت إجراء الجراحة .<br />إذا كنت قد خضعت إلى جراحة كبرى بمفصل الحوض فست تناول عادةً الأقراص لمدة 32 إلى 38 یومًا. وإذا كنت قد خضعت إلى جراحة كبرى بالركبة فست ناول عادةً الأقراص لمدة 10 إلى 14 یومًا.<br />في حالة الاستخدام لمنع تكوُّن الجلطات الدمویة في قلب لدي المرضى الذین یُعانون من عدم انتظام ضربات القلب ووجود عامل خطر إضافي واحد على الأقل .<br />الجرعة الموصى بھا ھي قرص واحد من أبیكسابان اس بي سي 5 مجم أقراص مرتان یومیًا.<br />الجرعة الموصى بھا ھي قرص واحد من أبیكسابان اس بي سي 2.5 مجم أقراص مرتان یومیًا في حالة :</p><p>إذا كنت تُع نا ي من اختلال وظیفيّ كلوي حاد. وإذا كان ینطبق علیك حالة أو أكث ر من الحالات التالیة :<br />&bull; تشیر نتائج اختبار الدَّم الخاص بك إلى وجود ضعف بوظائف الكُلى (مستوي الكریات ینین بالدمَّ ھي 1.5 مجم/ دیسیلتر [ 133 میكرومول/ لتر] أو<br />أكثر)<br />&bull; إذا كنت تبلغ من العمر 80 سنة أو أكثر.<br />&bull; إذا كان وزنك 60 كجم أو أقل .<br />&bull; الجرعة الموصى بھا ھي قرص واحد مرتان یومیًا، على سبیل المثال، قرص في الصباح وآخر في المساء .<br />سیقرر الطبیب المعالج لك المدة اللازمة للاستمرار في تلقي العلاج.</p><p>في حالة الاستخدام لعلاج الجلطات الدمویة في أوردة الساق والجلطات الدمویة في الأوعیة الدمویة ب الرئة .<br />الجرعة الموصى بھا ھي قرصان من أبیكسابان اس بي سي 5 مجم أقراص مرتان یومیًا لفترة أول 7 أیام، على سبیل المثال، قرصان في الصباح وقرصان في المساء .<br />تكون الجرعة الموصى بھا، بعد مرور 7 أیام، ھي قرص واحد مرتان یومیًا من أبیكسابان اس بي سي 5 مجم أقراص، على سبیل المثال قرص في الصباح وآخر في المساء .</p><p><strong>في حالة الاستخدام لمنع تكرار حدوث جلطات دمویة بعد إتمام ستة أشھر من العلاج</strong><br />الجرعة الموصى بھا ھي قرص واحد من أبیكسابان اس بي سي 2.5 مجم أقراص مرتان یومیًا، على سبیل المثال قرص واحد في الصباح وآخر في المساء.<br />&bull; سیقرر الطبیب المعالج لك المدة اللازمة للاستمرار في تلقي العلاج.</p><p><strong>قد یقوم الطبیب المعالج لك بتغییر العلاج المضاد للتجلط الخاص بك على النحو التَّالي :</strong><br />&bull; تغییر العلاج ب أبیكسابان اس بي سي أقراص إلى أدویة أخرى مضادة للتجلط :<br />توقف عن تناول أبیكسابان اس بي سي أقراص .<br /><strong>ابدأ العلاج بالأدویة المضادة للتجلط (مثل ھیبارین) في الموعد المحدد لتناوُل القرص التالي.</strong><br />&bull; تغییر العلاج بالأدویة الأخرى المضادة للتجلط إلى أبیكسابان اس بي س ي أقراص :<br />توقف عن تناوُل الأدویة المضادة للتجلط .<br />ابدأ العلاج ب أبیكسابان اس بي س ي في وقت تناوُل الجرعة التَّالیة من الدَّواء المضاد للتجلط، ثم استمر كالمعتاد.<br />&bull; تغییر العلاج بمضادات التجلط التي تحتوي على مناھضات فیتامین &quot;كیھ&quot; (مثل وارفارین) إلى أبیكسابان اس بي سي أقراص:<br />توقف عن تناول الدَّواء الذي یحتوي على مناھضات فیتامین &quot;كيه&quot;<br />یحتاج الطبیب المعالج لك إلى إجراء قیاسات للدم وإرشادك إلى وقت بدء تناوُل أبیكسابان اس بي سي أقراص.<br />&bull; تغییر العلاج ب أبیكسابان اس بي سي أقراص إلى العلاج بمضادات التجلط التي تحتوي على مناھضات فیتامین &quot;كیھ&quot; (مثل وارفارین) .<br />إذا أخبرك الطبیب المعالج لك أنھ یجب علیك تناول یحتوي على مناھضات فیتامین &quot;كیھ&quot;، فاستمر في تناوُل أبیكسابان اس بي سي أقراص&nbsp;<br />لمدة یومین على الأقل بعد تناوُل جرعتك الأولى من الدواء الذي یحتوي على مناھضات فیتامین &quot;كيه&quot;</p><p>یحتاج الطبیب المعالج لك إلى إجراء قیاسات للدم وإرشادك إلى الوقت المناسب للتَّو قف عن تناوُل أبیكسابان اس بي سي أقراص .</p><p><strong>في حالة المرضى الذین یخضعون لتقویم نظم القلب عن طریق الصدمة الكھربائیة :</strong></p><p>إذا كانت ھناك حاجة إلى إعادة نبضات القلب غیر الطبیعیة إلى طبیعتھا عن طریق إجراء یسمى تقویم نظم القلب عن طریق الصدمات الكھربائیة، یتم تناول<br />أبیكسا بان اس بي سي أقراص في الأوقات التي یحددھا الطبیب المعالج لك، لمنع تكون الجلطات في الأوعیة الدمویة في الدماغ والأوعیة الدمویة الأخرى<br />في الجسم</p><p><strong>إذا تناولت كمیة أكثر مما یجب من أبیكسابان اس بي سي أقراص</strong></p><p>أخبر الطبیب المعالج لك على الفو ر، إذا تناولت جرعة من أبیكسابان أقراص أكثر من تلك التي تم وصفھا لك. اصطحب معك عبوة الدواء، حتى إذا لم یكن<br />بھا أیة أقراص متبقیة.<br />إذا تناولت كمیة من أبیكسابان اس بي سي أقراص أكثر من الجرعة الموصى بھا، فقد یُؤدي ذلك إلى زیادة خطر تعرضك للنزیف. إذا حدث نزیف، فقد<br />. یستلزم الأمر إجراء جراحة أو نقل دم أو غیرھا من العلاجات التي قد تعكس فعالیة العامXa</p><p><strong>إذا أغف لت تناوُل أبیكسابان اس بي سي أقراص، اتبع ما یلي :</strong></p><p>&bull; قم بتناول الجرعة بمجرد تذكُّرك لھا،<br />&bull; تناول الجرعة التَّالیة من أبیكسابان اس بي سي أقراص في الموعد المعتاد.<br />&bull; ثم استمر في تناول الجرعات كالمعتاد.</p><p><strong>إذا لم تكن متأكدًا مما یجب القیام بھ أو أغفلت أكثر من جرعة واحدة،</strong></p><p>استشر الطبیب المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابع(ة) لحالتك.</p><p><strong>إذا توقفت عن تناول أبیكسابان اس بي سي أقراص .</strong></p><p>لا تتوقف عن تناوُل أبیكسابان اس بي سي أقراص دون التَّحدث إلى الطبیب المعالج لك أولًا؛ لأن نسبة خطورة حدوث تجلط في الدَّم قد تكون أك بر إذا<br />توقفت عن تناوُل العلاج في وقت مبكر جدًا .<br />إذا كانت لدیك أیة أسئلة إضافیة حول استخدام ھذا الدَّواء، فاستشر الطبیب المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابعة(ة) لحالتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد یُسبب ھذا الدواء، مثلھ م ثل كافة الأدویة، آثارً ا جانبیة، على الرغم من عدم حدوثھا لدى جمیع المرضى.<br />یمكن إعطاء أبیكسابان أقراص لعلاج ثلاث حالات طبیة مختلفة .<br />قد تختلف الآثار الجانبیة المعروفة ومدى تكرارھا في كل حالة من ھذه الحالات الطبیة المدرجة بشكل منفصل أدناه.<br />بالنسبة إلى ھذه الحالات، فإن الأثر الجان بي الأكثر شیوعًا لأبیكسابان اس بي سي أقراص ھو حدوث نزیف قد یكون مُھددًا للحیاة ویستدعي العنایة الطبیة الفوریة .<br />تُعَد الآثار الجانبیة التَّالیة معروفة إذا كنت تتناول أبیكسابان اس بي سي أقراص لمنع تكوُّن الجلطات الدَّمویة بعد جراحات استبدال مفصل الحوض أو الركبة.</p><p>آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من ب ین كل 10 مرضى):</p><p>&bull; فقر الدَّم (أنیمیا) والذي قد یُسبب شعورًا بالإرھاق أو شحوبًا.<br />&bull; نزیف ویشمل ما یلي :<br />تكدُّم وتورُّم، <br />غثیان (شعور بالإعیاء)</p><p><strong>آثار جانبیة غیر شائعة: (قد تُؤثر على ما یصل إلى مریض واحد من كل 100 مریض):</strong></p><p>&bull; انخفاض عدد الصفائح الدَّمویة في لا دم (مما قد یُؤثر على التَّجلط) .<br />&bull;نزیف: یحدث بعد إجراء جراحة بما في ذلك تكدُّم أو تورُّم أو تسرُّب الدم أو السوائل من الجرح/الشق الناتج عن الجراحة (إفرازات الجرح) أو موضع الحقن في المعدة أو الأمعاء أو دماء حمراء/ذات لون فاتح في البراز أو دم في البول أو نزیف من الأنف أو من المھبل .<br />&bull; انخفاض ضغط الدَّم الذي قد یجعلك تشعر بالإغماء أو سرعة ضربات القلب .<br />&bull; قد تُظھر اختبارات الدم: نتائج غیر طبیعیة في وظائف الكبد (ارتفاع في إنزیمات الكبد أو ارتفاع نس بة البیلیروبین، أحد نواتج تكسیر كریات الدم الحمراء، مما قد یسبب اصفرار الجلد والعی نین).<br />&bull; حكة</p><p><strong>آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من كل 1.000 مریض)</strong></p><p>- تفاعلات حساسیة (فرط الحساسیة) قد تسبب: تورم الوجھ، الشفتین أو الفم أو اللسان و/أو الحلق وصعوبة في التنفس. اتصل بالطبیب المعالج لك<br />على الفور إذا عانیت من أي من ھذه الأعراض .<br />- نزیف في العضلا ت أو في العین أو نزیف من اللثة ووجود دم في البصاق عند السُّعال أو نزیف من المستقیم.</p><p><strong>أثار جانبیة غیر معروفة (لا یمكن تقدیر معدل تكرارھا من واقع البیانات المتاحة )</strong></p><p>- نزی ف في الدماغ أو في العمود الفقري أو في الرئتین أو الحلق أو في الفم أو في البطن أو في المنطقة الموجودة خلف تجویف البطن أو نزیف من<br />البواسیر أو أن تظھر الاختبارات وجود دم في البراز أو في البول .<br />- طفح جلد ي<br />تُعَد الآثار الجانبیة التَّالیة معروفة إذا كنت تتناول أیب كسابان اس بي س ي أقر اص لمنع تكوُّن الجلطات الدَّمویة في القلب لدي المرضى الذین یُعانون من عدم<br />انتظام ضربات القلب ووجود عامل خطر إضافي واحد على الأقل .</p><p><strong>آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل 10 مرضى):</strong></p><p>&bull; نزیف ویشمل نزیف في العینین أو في المعدة أو في الامعاء أو نزیف من المستقیم أو وجود دم في البول أو نزیف من الأنف أو من اللثة أو تكدم<br />وتورم .<br />&bull; فقر الدَّم (أنیمیا) والذي قد یُسبب شعورًا بالإرھاق أو شحوبًا.<br />&bull; انخفاض ضغط الدَّم الذي قد یجعلك تشعر بالإغماء أو سرعة ضربات القلب .<br />&bull; غثیان (شعورًا بالإعیاء).<br />.&bull; قد تظھر اختبارات الدم: ارتفاع مستوى إنزیم ناقلة الجاما جلوتامایل(GGT)</p><p><strong>آثار جانبیة غیر شائعة: (قد تُؤثر على ما یصل إلى مریض واحد من بین كل 100 مریض):</strong></p><p>&bull; نزیف في المخ أو في العمود الفقري نزیف من الفم أو وجود دم في البصاق عند السُّعال أو نزیف في البطن أو من المھبل أو وجود دم أحمر/فاتح<br />اللون في البراز، أو حدوث نزیف عقب إجراء جراحة بما في ذلك تكدُّم وتورُّم أو تسرُّب الدم أو السوائل من الجرح / الشق الناتج عن الجراحة<br />(إفرازات الجرح) أو موضع الحقن، أو نزیف من البواسیر أو أن تظھر الاختبارات وجود دم في البراز أو في البول .<br />&bull; انخفاض عدد الصفائح الدَّمویة في لا دم (مما قد یُؤثر على التَّجلط) .<br />&bull; قد تُظھر اختبارات الدم نتائج غیر طبیعیة بوظائف الكبد (زیادة في إنزیمات الكبد أو ارتفاع نسبة البیلیروبین، أحد نواتج تكسیر كریات الدم<br />الحمراء، مما قد یسبب اصفرارًا الجلد والعینین.<br />&bull; طفح جلد ي<br />&bull; حكة<br />&bull; تساقط ا لشعر<br />&bull; تفاعلات حساسیة (فرط الحساسیة) قد تسبب: تورم الوجھ أو الشفتین أو الفم، اللسان و/أو الحلق وصعوبة في التنفس. اتصل بالطبیب المعالج لك<br />على الفور إذا عانیت من أي من ھذه الأعراض</p><p><strong>آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مریض واحد من كل 1.000 مریض)</strong></p><p>&bull; ن زیف في الرئتین أو الحلق أو في المنطقة الموجودة خلف تجویف البطن أو في العضلا ت.<br />تع د الآثار الجانبیة التَّالیة معروفة إذا كنت تتناول أبیكسابان اس بي سي أقراص لعلاج أو لمنع إعادة تكوُّن الجلطات الدَّمویة في أوردة لا ساق والأوعیة<br />الدمویة ب الرئ ة.</p><p><strong>آثار جانبیة شائعة (قد تُؤثر على ما یصل إلى مریض واحد من بین كل 10 مرضى):</strong></p><p>&bull; نزیف ویشمل: نزیف من الأنف أو من اللثة أو دم في البول أو تكدم وتورم أو نزف في المعدة أو في الأمعاء أو نزیف من المستقیم أو نزیف بالفم<br />أو من المھبل.<br />&bull; فقر الدَّم (أ نیمیا) والذي قد یُسبب شعورًا بالإرھاق أو الشحوب.<br />&bull; انخفاض عدد الصفائح الدَّمویة في لا دم (مما قد یُؤثر على التَّجلط) .<br />&bull; غثیان (شعور بالإعیاء).<br />&bull; طفح جلدي .<br />. &bull; قد تظھر اختبارات الدم: ارتفاع مستوى إنزیم ناقلة الجاما جلوتامایل(GGT) أو ناقلة الأمین الألانینیة ((ALT)</p><p><strong>آثار جانبیة غیر شائعة: (قد تُؤثر على ما یصل إلى مریض واحد من بین كل 100 مریض):</strong></p><p>&bull; انخفاض ضغط الدَّم الذي قد یجعلك تشعر بالإغماء أو تسارع ضربات القلب .<br />&bull; نزیف: في العینین، في الفم أو وجود دم في البصاق عند السُّعال أو وجود دم أحمر/فاتح اللون في البراز أو أن تظھر الاختبارات وجود دم في<br />البراز أو في البول، حد وث نزیف عقب إجراء جراحة بما في ذلك تكدُّم وتورُّم، تسرُّب الدم أو السوائل من الجرح/الفتحة الناتجة عن الجراحة<br />(إفرازات الجرح) أو موضع الحقن أو نزیف من البواسیر أو نزیف في العضلات.<br />&bull; حكة.<br />&bull; تساقط الشعر<br />&bull; تفاعلات حساسیة (فرط الحساسیة) قد تسبب: تورم الوجھ أو الشفتین أو الفم أو اللسان و/أو الحلق وصعوبة في التنفس. اتصل بالطبیب المعالج<br />لك على الفور إذا عانیت من أي من ھذه الأعراض .<br />&bull; قد تُظھر اختبارات الدم نتائج غیر طبیعیة بوظائف الكبد (زیادة في بعض إنزیمات الكبد أو ارتفاع نسبة البیلیروبین، أحد نواتج تكسیر كریات الدم<br />الحمراء، مما قد یسبب اصفرارًا الجلد والعینین)</p><p><strong>آثار جانبیة نادرة (قد تُؤثر على ما یصل إلى مر یض واحد من كل 1,000 مریض)</strong></p><p>&bull; نزیف في المخ أو العمود الفقري أو في الرئتین.</p><p><strong>آثار جانبیة غیر معروفة (لا یمكن تقدیر معدل تكرارھا من واقع البیانات المتاحة)</strong><br />&bull; نزیف في البطن أو في المنطق ة الموجودة خلف تجویف البطن.</p><p><strong>الإبلاغ عن الآثار الجانبیة</strong><br />إذا أُصبت بأیة آثار جانبیة، فتحدَّث إلى الطبیب المعالج لك أو الصیدلي الخاص بك أو الممرض(ة) المتابع(ة) لحالتك. ویشمل ذلك أيّ آثار جانبیة مُحتملة غیر مُدرجة في ھذه ال نَّشرة .<br />. npc.drug@sfda.gov.sa : یمكنك أیضًا الإبلاغ عن الآثار الجا نبیة مباشرةً عن طریق إرسال النماذج المعبأة إلى البرید الالكترونى عن طریق الإبلاغ عن الآثار الجانبیة ، یمكنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحُفظ ھذا الدَّواء بعیدًا عن متناول ورؤیة الأطفال .<br />EXP&quot; لا تستعمل ھذا الدَّواء بعد تاریخ انتھاء الصلاحیة المدون على العبوة الكرتونیة والشریط بعد كلمة .&quot;<br />لا تقم بتخزینھ عند درجة حرارة تزید عن 30 درجة مئوی ة<br />ابقھ بعیدا عن الضوء و الرطوب ة<br />یُشیر تاریخ انتھاء الصلاحیة إلى الیوم الأخیر من ذلك الشھر .<br />لا یتطلب ھذا الدَّواء أیة شروط خاصة لل تخزین .<br />لا تتخلص من الأدویة عن طریق إلقائھا في میاه الصرف الصحي أو مع النفایات المنزلیة.<br />استشر الصیدلي الخاص بك حول كیفیة التَّخلص من الأدویة التي لم تعد تستخدمھا. حیث ستساعد تلك الإجراءات على حمایة ال بیئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>یحتوي كل قرص مغلف على 2.5 مجم من أ بیكسابان.</p><p>تشمل المكونات الأخرى ما یلي :<br />&bull; محتوى القرص الدَّاخلي: لاكتوز أحادي الھیدرات، سلیلوز دقیق التَبلّور PH&nbsp;101كروسكارمیلوز الصودیوم، سلفات لوریل الصودیوم، ماء منقى، ستیرات الماغنسیوم.<br />أ &bull; طبقة القرص الخارجی ة: أوبادري II اصفر 32K520116</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص مغلفة دائریة الشكل ثنائیة التحدب باللون الأصفر محفور على أحد جانبیھا.&quot; &quot;M&quot; وعلى الجانب الآخر &quot; 2.5</p><p>عبوات شرائط مصنوعة من الألومنیوم/ بولي فینیل الكلورید/ بولي فینیلیدین كلورید یحتوي كل منھا على 10 أقراص.<br />عبوة كبیرة تحتوي على 60 قرص أو 200 قرص أو 1000 قرص. قد لا یتم تسویق جمیع أحجام العبوات .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق<br />(SPC) شركة سدیر فارما<br />طریق الملك فھد، مبنى رقم 911 - الدوران الأول، الریاض، المملكة العربیة السعودیة .<br />هاف رقم 00966114668193<br />- فاكس رقم: 00966114668195</p><p>البر ید الإلكتروني:info@sudairpharma.com<br />عنوان المراسلة: صندوق برید : 19047 الریاض، المملكة العربیة السعودی ة<br />جھة التصنیع :<br />مختبرات إم إس إن الخاصة المحد ودة<br />1319 حتى 1324 ، ناندیجاما، (فیلدج وماندال)، ، قسم التركیبات الصیدلا نیة، وحدة رقم 2، مناطق تقسیم رقم 1277<br />من طقة رانجاریدي، تالینجانا 509228 ، الھند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            01/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apixaban SPC 5 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains Apixaban 5mg. Product contains Lactose.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)
Pink, oval , biconvex , film coated tablets , debossed with "M" on one side and "5" on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age&ge; 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHAClass &ge; II).<br />Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><strong>Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)</strong>,</p><p>The recommended dose of apixaban is 5 mg taken orally twice daily.<br /><strong>Dose reduction</strong><br />The recommended dose of apixaban is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age &ge; 80 years, body weight &le; 60 kg, or serum creatinine &ge; 1.5 mg/dL (133 micromole/L). Therapy should be continued long-term.<br /><strong>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</strong><br />The recommended dose of apixaban for the treatment of acute DVT and treatment of PE is 10 mg taken orally twicedaily for the first 7 days followed by 5 mg taken orally twice daily. As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g., recent surgery, trauma, immobilisation).<br />The recommended dose of apixaban for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily. When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with apixaban 5 mg twice daily or with another anticoagulant, as indicated in Table 1 below (see also section 5.1)</p><p><strong>Table 1:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:224px">&nbsp;</td><td style="width:209px">Dosing schedule</td><td style="width:66px">Maximum daily dose</td></tr><tr><td rowspan="2" colspan="1" style="width:224px">Treatment of DVT or PE</td><td style="width:209px">10 mg twice daily for the first 7 days</td><td style="width:66px">20 mg</td></tr><tr><td style="width:209px">followed by 5 mg twice daily</td><td style="width:66px">10 mg</td></tr><tr><td style="width:224px">Prevention of recurrent DVT and/or PE following completion of 6 months of treatment for DVT or PE</td><td style="width:209px">2.5 mg twice daily</td><td style="width:66px">5 mg</td></tr></tbody></table><p>The duration of overall therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4).</p><p><strong>Missed dose </strong></p><p>If a dose is missed, the patient should take Apixaban SPC immediately and then continue withtwice daily intake as before.</p><p><strong>Switching</strong></p><p>Switching treatment from parenteral anticoagulants to Apixaban SPC (and vice versa) can be done atthe next scheduled dose (see section 4.5).&nbsp; These medicinal products should not be administered simultaneously.</p><p><strong>Switching from vitamin K antagonist (VKA) therapy to Apixaban SPC</strong></p><p>When converting patients from vitamin K antagonist (VKA) therapy to Apixaban SPC, warfarinor other VKA therapy should be discontinued and Apixaban SPC started when the internationalnormalised ratio (INR) is &lt; 2.</p><p><strong>Switching from Apixaban SPC to VKA </strong></p><p>therapyWhen converting patients from Apixaban SPC to VKA therapy, administration ofApixaban SPC should be continued for at least 2 days after beginning VKA therapy. After 2 days ofcoadministration of Apixaban SPC with VKA therapy, an INR should be obtained prior to the nextscheduled dose of Apixaban SPC. Coadministration of Apixaban SPC and VKA therapy should becontinued until the INR is &ge; 2.</p><p><strong>Renal impairment </strong></p><p>In patients with mild or moderate renal impairment, the following recommendations apply:</p><p>- for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), no dose adjustment is necessary (see section 5.2).</p><p>- for the prevention of stroke and systemic embolism in patients with NVAF and serum creatinine &ge;1.5 mg/dL (133 micromole/L) associated with age &ge;80 years or body weight &le;60 kg, a dose reduction is necessary and described above.</p><p>In the absence of other criteria for dose reduction (age, body weight), no dose adjustment is necessary (see section 5.2).</p><p>In patients with severe renal impairment (creatinine clearance 15-29 mL/min) the following recommendations apply (see sections 4.4 and 5.2):</p><p>- for the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) apixaban is to be used with caution;</p><p>- for the prevention of stroke and systemic embolism in patients with NVAF, patients should receive the lower dose of apixaban 2.5 mg twice daily.</p><p>In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.4 and 5.2).</p><p><strong>Hepatic impairment</strong></p><p>Apixaban SPC is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3). It is not recommended in patients with severe hepatic impairment (see sections 4.4. and 5.2). It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B). No dose adjustment is required in patients with mild or moderate hepatic impairment (see sections 4.4 and 5.2).</p><p>Patients with elevated liver enzymes alanine aminotransferase (ALT)/aspartate aminotransferase (AST) &gt;2 x ULN or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore Apixaban SPC should be used with caution in this population (see sections 4.4 and 5.2). Prior to initiating Apixaban SPC, liver function testing should be performed</p><p><strong>Body weight </strong></p><p>VTEt - No dose adjustment required (see sections 4.4 and 5.2). NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2).</p><p><strong>Gender </strong></p><p>No dose adjustment required (see section 5.2).</p><p><strong>Elderly</strong></p><p>VTEt - No dose adjustment required (see sections 4.4 and 5.2). NVAF - No dose adjustment required, unless criteria for dose reduction are met (see Dose reduction at the beginning of section 4.2). Patients undergoing catheter ablation (NVAF).Patients can continue apixaban use while undergoing catheter ablation.</p><p><strong>Patients undergoing cardioversion</strong></p><p>Apixaban can be initiated or continued in NVAF patients who may require cardioversion. For patients not previously treated with anticoagulants, exclusion of left atrial thrombus using an image guided approach (e.g. transesophogeal echocardiography (TEE) or computed tomographic scan (CT)) prior to cardioversion should be considered, in accordance with established medical guidelines.</p><p>For patients initiating treatment with apixaban, 5 mg should be given twice daily for at least 2.5 days (5 single doses) before cardioversion to ensure adequate anticoagulation (see section 5.1). The dosing regimen should be reduced to 2.5 mg apixaban given twice daily for at least 2.5 days (5 single doses) if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment).If cardioversion is required before 5 doses of apixaban can be administered, a 10 mg loading dose should be given, followed by 5 mg twice daily.</p><p>The dosing regimen should be reduced to a 5 mg loading dose followed by 2.5 mg twice daily if the patient meets the criteria for dose reduction (see above sections Dose reduction and Renal impairment). The administration of the loading dose should be given at least 2 hours before cardioversion (see section 5.1). For all patients undergoing cardioversion Confirmation should be sought prior to cardioversion that the patient has taken apixaban as prescribed. Decisions on initiation and duration of treatment should take established guideline recommendations for anticoagulant treatment in patients undergoing cardioversion into account.</p><p><strong>Paediatric population </strong></p><p>The safety and efficacy of Eliquis in children and adolescents below age 18 have not been established. No data are available</p><p><strong>Method of administration</strong></p><p>Oral use Apixaban SPC should be swallowed with water, with or without food.For patients who are unable to swallow whole tablets, Apixaban SPC tablets may be crushed and suspended in water, or 5% dextrose in water (D5W), or apple juice or mixed with apple puree and immediately administered orally (see section 5.2). Alternatively, Eliquis tablets may be crushed and suspended in 60 mL of water or D5W and immediately delivered through a nasogastric tube (see section 5.2).Crushed Eliquis tablets are stable in water, D5W, apple juice, and apple puree for up to 4 hours</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•Active clinically significant bleeding.
•Hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section5.2).
•Lesion or condition if considered a significant risk factor for major bleeding. This may includecurrent or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk ofbleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery,recent intracranial haemorrhage, known or suspected oesophageal varices,arteriovenous malformations, vascular aneurysms or major intraspinal orintracerebral vascular abnormalities.•Concomitant treatment with any other anticoagulant agent e.g., unfractionated heparin (UFH),low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives(fondaparinux, etc.), oral anticoagulants (warfarin, rivaroxaban, dabigatran, etc.) except underspecific circumstances of switching anticoagulant therapy (see section 4.2) when UFH isgiven at doses necessary to maintain an open central venous or arterial catheter or whenUFH is given during catheter ablation for atrial fibrillation (see sections 4.4 and 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Haemorrhage risk</strong></p><p>As with other anticoagulants, patients taking Apixaban SPC are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Apixaban SPC administration should be discontinued if severe haemorrhage occurs (see sections 4.8 and 4.9). Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery (see section 5.1). An agent to reverse the anti-factor Xa activity of apixaban is available.</p><p><strong>Interaction with other medicinal products affecting haemostasis</strong></p><p>Due to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated (see section 4.3). The concomitant use of Apixaban SPC with antiplatelet agents increases the risk of bleeding(see section 4.5). Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.</p><p>Following surgery, other platelet aggregation inhibitors are not recommended Apixaban SPC (see section 4.5).<br />In patients with atrial fibrillation and conditions that warrant mono or dual antiplatelet therapy, a careful assessment of the potential benefits against the potential risks should be made before combining this therapy with Apixaban SPC.In a clinical trial of patients with atrial fibrillation, concomitant use of ASA increased the major bleeding risk on apixaban from 1.8% per year to 3.4% per year and increased the bleeding risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.1%) use of concomitant dual antiplatelet therapy.</p><p>In a clinical trial of high-risk post-acute coronary syndrome patients, characterised by multiple cardiac and non-cardiac comorbidities, who received ASA or the combination of ASA and clopidogrel, a significant increase in risk of ISTH (International Society on Thrombosis and Haemostasis) major bleeding was reported for apixaban (5.13% per year) compared to placebo (2.04% per year).</p><p><strong>Use of thrombolytic agents for the treatment of acute ischemic stroke</strong></p><p>There is very limited experience with the use of thrombolytic agents for the treatment of acute ischemic stroke in patients administered apixaban</p><p><strong>Patients with prosthetic heart valves</strong></p><p>Safety and efficacy of Apixaban SPC have not been studied in patients with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of Eliquis is not recommended in this setting.Patients with antiphospholipid syndromeDirect Acting Oral Anticoagulants (DOACs) including apixaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><strong>Surgery and invasive procedures</strong></p><p>Apixaban SPC should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of bleeding. This includes interventions for which the probability of clinically significant bleeding cannot be excluded or for which the risk of bleeding would be unacceptable. Apixaban SPC should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding. This includes interventions for which any bleeding that occurs is expected to be minimal, non-critical in its location or easily controlled. If surgery or invasive procedures cannot be delayed, appropriate caution should be exercised, taking into consideration an increased risk of bleeding. This risk of bleeding should be weighed against the urgency of intervention. Apixaban SPC should be restarted after the invasive procedure or surgical intervention as soon as possible provided the clinical situation allows and adequate haemostasis has been established (for cardioversion see section 4.2). For patients undergoing catheter ablation for atrial fibrillation, Apixaban treatment does not need to be interrupted (see sections 4.2, 4.3 and 4.5).</p><p><strong>Temporary discontinuation</strong></p><p>Discontinuing anticoagulants, including Apixaban SPC, for active bleeding, elective surgery, or invasive procedures places patients at an increased risk of thrombosis. Lapses in therapy should be avoided and if anticoagulation with Apixaban SPC must be temporarily discontinued for any reason, therapy should<br />be restarted as soon as possible</p><p><strong>Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy</strong></p><p>Apixaban SPC is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy since the safety and efficacy of apixaban have not been established in these clinical situations</p><p><strong>Patients with active cancer</strong></p><p>Efficacy and safety of apixaban in the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt) in patients with active cancer have not been established</p><p><strong>Patients with renal impairment</strong></p><p>Limited clinical data indicate that apixaban plasma concentrations are increased in patients with severe renal impairment (creatinine clearance 15-29 mL/min) which may lead to an increased bleeding risk. For the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and 5.2). For the prevention of stroke and systemic embolism in patients with NVAF, patients with severe renal impairment (creatinine clearance 15-29 mL/min), and patients with serum creatinine &ge; 1.5 mg/dL (133 micromole/L) associated with age &ge; 80 years or body weight &le; 60 kg should receive the lower dose of apixaban 2.5 mg twice daily (see section 4.2); In patients with creatinine clearance &lt; 15 mL/min, or in patients undergoing dialysis, there is no clinical experience therefore apixaban is not recommended (see sections 4.2 and 5.2).</p><p><strong>Elderly patients</strong></p><p>Increasing age may increase haemorrhagic risk (see section 5.2). Also, the co-administration of Apixaban SPC with ASA in elderly patients should be used cautiously because of a potentially higher bleeding risk</p><p><strong>Body weight</strong></p><p>Low body weight (&lt; 60 kg) may increase haemorrhagic risk (see section 5.2).</p><p><strong>Patients with hepatic impairment</strong></p><p>Apixaban SPC is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk (see section 4.3). It is not recommended in patients with severe hepatic impairment (see section 5.2). It should be used with caution in patients with mild or moderate hepatic impairment (Child Pugh A or B)(see sections 4.2 and 5.2).</p><p>Patients with elevated liver enzymes ALT/AST &gt; 2 x ULN or total bilirubin &ge; 1.5 x ULN were excluded in clinical trials. Therefore, Apixaban SPC should be used cautiously in this population (seesection 5.2). Prior to initiating Apixaban SPC, liver function testing should be performed</p><p><strong>Interaction with inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp)</strong></p><p>The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir). These medicinal products may increase apixaban exposure by 2-fold (see section 4.5) or greater in the presence of additional factors that increase apixaban exposure (e.g., severe renal impairment).</p><p><strong>Interaction with inducers of both CYP3A4 and P-gp</strong></p><p>The concomitant use of Apixaban SPC with strong CYP3A4 and P-gp inducers (e.g., rifampicin,phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort) may lead to a ~50% reduction in apixaban exposure. In a clinical study in atrial fibrillation patients, diminished efficacy and a higher risk of bleeding were observed with coadministration of apixaban with strong inducers of both CYP3A4 and P-gp compared with using apixaban alone. In patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P- gp the following recommendations apply (see section 4.5):<br />&bull;for the prevention of stroke and systemic embolism in patients with NVAF and for theprevention of recurrent DVT and PE, apixaban should be used with caution;<br />&bull;for the treatment of DVT and treatment of PE, apixaban should not be used since efficacymay be compromised.</p><p><strong>Laboratory parameters</strong></p><p>Clotting tests [e.g., prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT)] are affected as expected by the mechanism of action of apixaban. Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability (see section 5.1). Information about excipients Apixaban SPC contains lactose. Patients with rare hereditary problems of galactose intolerance,the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Inhibitors of CYP3A4 and P-gp</strong></p><p>Coadministration of apixaban with ketoconazole (400 mg once a day), a strong inhibitor of both CYP3A4 and P-gp, led to a 2-fold increase in mean apixaban AUC and a 1.6-fold increase in mean apixaban Cmax.<br />The use of Apixaban SPC is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, itraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see section 4.4). Active substances which are not considered strong inhibitors of both CYP3A4 and P-gp, (e.g., diltiazem, naproxen, clarithromycin, amiodarone, verapamil, quinidine) are expected to increase apixaban plasma concentration to a lesser extent. No dose adjustment for apixaban is required when coadministered with agents that are not strong inhibitors of both CYP3A4 and P-gp. For example, diltiazem (360 mg once a day), considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean apixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. Clarithromycin (500 mg, twice a day), an inhibitor of P-gp and a strong inhibitor of CYP3A4, led to a 1.6-fold and 1.3-fold increase in mean apixaban AUC and Cmax respectively.</p><p><strong>Inducers of CYP3A4 and P-gp</strong></p><p>Coadministration of apixaban with rifampicin, a strong inducer of both CYP3A4 and P-gp, led to an approximate 54% and 42% decrease in mean apixaban AUC and Cmax, respectively. The concomitant use of apixaban with other strong CYP3A4 and P-gp inducers (e.g., phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort) may also lead to reduced apixaban plasma concentrations. No dose adjustment for apixaban is required during concomitant therapy with such medicinal products, however in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp apixaban should be used with caution for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE. Apixaban is not recommended for the treatment of DVT and PE in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp since efficacy may be compromised (see section 4.4).</p><p><strong>Anticoagulants, platelet aggregation inhibitors SSRIs/SNRIs and NSAIDs</strong></p><p>Anticoagulants, platelet aggregation inhibitors SSRIs/SNRIs and NSAIDsDue to an increased bleeding risk, concomitant treatment with any other anticoagulants is contraindicated except under specific circumstances of switching anticoagulant therapy, when UFH is given at doses necessary to maintain an open central venous or arterial catheter or when UFH is given during catheter ablation for atrial fibrillation (see section 4.3).After combined administration of enoxaparin (40 mg single dose) with apixaban (5 mg single dose), an additive effect on anti-Factor Xa activity was observed. Pharmacokinetic or pharmacodynamic interactions were not evident when apixaban was<br />coadministered with ASA 325 mg once a day. Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel 75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone. Naproxen (500 mg), an inhibitor of P-gp, led to a 1.5-fold and 1.6-fold increase in mean apixaban AUC and Cmax, respectively. Corresponding increases in clotting tests were observed for apixaban. No changes were observed in the effect of naproxen on arachidonic acid-induced platelet aggregation and no clinically relevant prolongation of bleeding time was observed after concomitant administration of apixaban and naproxen. Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are coadministered with apixaban. Apixaban SPC should be used with caution when coadministered with SSRIs/SNRIs NSAIDs (including acetylsalicylic acid)because these medicinal products typically increase the bleeding risk. A significant increase in bleeding risk was reported with the triple combination of apixaban, ASA and clopidogrel in a clinical study in patients with acute coronary syndrome (see section 4.4).</p><p>Medicinal products associated with serious bleeding are not recommended concomitantly with Apixaban SPC, such as: thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran and sulfinpyrazone</p><p><strong>Other concomitant therapies</strong></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when apixaban was coadministered with atenolol or famotidine. Coadministration of apixaban 10 mg with atenolol 100 mg did not have a clinically relevant effect on the pharmacokinetics of apixaban. Following administration of the two medicinal products together, mean apixaban AUC and Cmax were 15% and 18% lower than when administered alone. The administration of apixaban 10 mg with famotidine 40 mg had no effect on apixaban AUC or Cmax.</p><p><strong>Effect of apixaban on other medicinal products</strong></p><p>In vitro apixaban studies showed no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6 or CYP3A4 (IC50 &gt; 45 &mu;M) and weak inhibitory effect on the activity of CYP2C19 (IC50 &gt; 20 &mu;M) at concentrations that are significantly greater than peak plasma concentrations observed in patients. Apixaban did not induce CYP1A2, CYP2B6, CYP3A4/5 at a concentration up to 20 &mu;M. Therefore, apixaban is not expected to alter the metabolic clearance of<br />coadministered drugs that are metabolised by these enzymes. Apixaban is not a significant inhibitor of P-gp.<br />In studies conducted in healthy subjects, as described below, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, or atenolol</p><p><strong>Digoxin</strong></p><p>Coadministration of apixaban (20 mg once a day) and digoxin (0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax. Therefore, apixaban does not inhibit P-gp mediated substrate transport.</p><p><strong>Naproxen</strong></p><p>Coadministration of single doses of apixaban (10 mg) and naproxen (500 mg), a commonly used NSAID, did not have any effect on the naproxen AUC or Cmax.</p><p><strong>Atenolol</strong></p><p>Coadministration of a single dose of apixaban (10 mg) and atenolol (100 mg), a common beta- blocker, did not alter the pharmacokinetics of atenolol</p><p><strong>Activated charcoal</strong></p><p>Administration of activated charcoal reduces apixaban exposure (see section 4.9).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no data from the use of apixaban in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Apixaban is not recommended during pregnancy.</p><p><strong>Breast-feeding</strong></p><p>It is unknown whether apixaban or its metabolites are excreted in human milk. Available data in animals have shown excretion of apixaban in milk. In rat milk, a high milk to maternal plasma ratio (Cmax about 8, AUC about 30) was found, possibly due to active transport into the milk. A risk to newborns and infants cannot be excluded.<br />A decision must be made to either discontinue breast-feeding or to discontinue/abstain from apixaban therapy.</p><p><strong>Fertility</strong></p><p>Studies in animals dosed with apixaban have shown no effect on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Eliquis has no or negligible influence on the ability to drive and use machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The safety of apixaban has been investigated in 7 Phase III clinical studies including more than 21,000 patients: more than 5,000 patients in VTEp studies, more than 11,000 patients in NVAF studies and more than 4,000 patients in the VTE treatment (VTEt) studies, for an average total exposure of 20 days, 1.7 years and 221 days respectively (see section 5.1).<br />Common adverse reactions were hemorrhage, contusion, epistaxis, and hematoma (see Table 2 for adverse reaction profile and frequencies by indication).<br />In the VTEp studies, in total, 11% of the patients treated with apixaban 2.5 mg twice daily experienced adverse reactions. The overall incidence of adverse reactions related to bleeding with apixaban was 10% in the apixaban vs enoxaparin studies.<br />In the NVAF studies, the overall incidence of adverse reactions related to bleeding with apixaban was 24.3% in the apixaban vs warfarin study and 9.6% in the apixaban vs acetylsalicylic acid study.<br />In the apixaban vs warfarin study the incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) with apixaban was 0.76%/year. The incidence of ISTH major intraocular bleeding with apixaban was 0.18%/year.<br />In the VTEt studies, the overall incidence of adverse reactions related to bleeding with apixaban was 15.6% in the apixaban vs enoxaparin/warfarin study and 13.3% in the apixaban vs placebo study (see section 5.1).<br /><strong>Tabulated list of adverse reactions</strong><br />Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data) for VTEp, NVAF, and VTEt respectively.</p><p><strong>Table 2:</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:775px"><tbody><tr><td><p>System Organ Class</p></td><td><p>Prevention of VTE in<br />Adult patients who<br />have undergone<br />elective hip or knee<br />replacement surgery<br />(VTEp)</p></td><td><p>Prevention of stroke and<br />systemic embolism in<br />adult patients with NVAF,<br />with one or more risk<br />factors (NVAF)</p></td><td><p>Treatment of DVT<br />and PE, and<br />prevention of<br />recurrent DVT and<br />PE (VTEt)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Blood and lymphatic system disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anemia</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Immune system disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypersensitivity, allergic oedema and Anaphylaxis</p></td><td><p>Rare</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pruritus</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon*</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Nervous system disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Brain haemorrhage&dagger;</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Eye disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Eye hemorrhage (including conjunctival hemorrhage)</p></td><td><p>Rare</p></td><td><p>Common</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Vascular disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hemorrhage, hematoma</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypotension (including<br />procedural hypotension)</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Intra-abdominal<br />hemorrhage</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Not known</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Epistaxis</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hemoptysis</p></td><td><p>Rare</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Respiratory tract<br />hemorrhage</p></td><td><p>Not known</p></td><td><p>Rare</p></td><td><p>Rare</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Gastrointestinal disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gastrointestinal<br />haemorrhage</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Haemorrhoidal<br />haemorrhage</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Mouth haemorrhage</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Haematochezia</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rectal haemorrhage,<br />gingival bleeding</p></td><td><p>Rare</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Retroperitoneal<br />haemorrhage</p></td><td><p>Not known</p></td><td><p>Rare</p></td><td><p>Not known</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Hepatobiliary disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Liver function test<br />abnormal, asparate<br />aminotransferase<br />increased, blood alkaline<br />phosphatase increased,<br />blood bilirubin increased</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Gammaglutamyltransferase<br />increased</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Alanine<br />aminotransferase<br />increased</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Skin and subcutaneous tissue disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Skin rash</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Alopecia</p></td><td><p>Rare</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Musculoskeletal and connective tissue disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle hemorrhage</p></td><td><p>Rare</p></td><td><p>Rare</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Renal and urinary disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Haematuria</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Reproductive system and breast disorders</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Abnormal vaginal<br />hemorrhage, urogenital<br />hemorrhage</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>General disorders and administration site conditions</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Application site bleeding</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Investigations</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Occult blood positive</p></td><td><p>Not known</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4"><p>Injury, poisoning and procedural complications</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Contusion</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Post procedural</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p>Traumatic hemorrhage</p></td><td rowspan="2"><p>Not known</p></td><td rowspan="2"><p>Uncommon</p></td><td rowspan="2"><p>Uncommon</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr></tbody></table><p>*There were no occurrences of generalized pruritus in CV185057 (long term prevention of VTE) &dagger;The term &quot;Brain hemorrhage&quot; encompasses all intracranial or intraspinal&nbsp; emorrhages (ie., haemorrhagic stroke or putamen, cerebellar, intraventricular, or subdural haemorrhages).<br />The use of Apixaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anemia.</p><p>The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see sections 4.4 and 5.1).<br /><strong>Reporting of suspected adverse reactions:</strong><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via submitting completed forms to: npc.drug@sfda.gov.sa.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose of apixaban may result in a higher risk of bleeding. In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated. The initiation of appropriate treatment, e.g., surgical haemostasis or the transfusion of fresh frozen plasma or the administration of a reversal agent for factor Xa inhibitors should be considered.<br />In controlled clinical trials, orally-administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily (bid) for 7 days or 50 mg once daily (od) for 3 days) had no clinically relevant adverse effects.<br />In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20 mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively, and had no impact on Cmax. Mean half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental<br />ingestion.<br />For situations when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, a reversal agent for factor Xa inhibitors is available (see section 4.4). A administration of prothrombin complex concentrates (PCCs) or recombinant factor VIIa also may be considered. Reversal of Apixaban pharmacodynamic effects, as demonstrated by changes in the thrombin generation assay, was evident at the end of infusion and reached baseline values within 4 hours after the start of a 4-factor PCC 30-minute infusion in healthy subjects. However, there is no clinical experience with the use of 4-factor PCC products to reverse bleeding in individuals who have received Apixaban. Currently there is no experience with the use of recombinant factor VIIa in individuals receiving apixaban. Re-dosing of recombinant factor VIIa could be considered and titrated depending on improvement of bleeding.<br />Depending on local availability, a consultation of a coagulation expert should be considered in case of major bleedings.<br />Haemodialysis decreased apixaban AUC by 14% in subjects with end-stage renal disease (ESRD), when a single dose of apixaban 5 mg was administered orally. Therefore,&nbsp; aemodialysis is unlikely to be an effective means of managing apixaban overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Mechanism of action</strong><br />Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development. Preclinical studies of apixaban in animal models have demonstrated antithrombotic efficacy in the prevention of arterial and venous thrombosis at doses that preserved haemostasis.<br /><strong>Pharmacodynamic effects</strong><br />The pharmacodynamic effects of apixaban are reflective of the mechanism of action (FXa inhibition). As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose are small and subject to a high degree of variability. They are not recommended to assess the pharmacodynamic effects of apixaban. In the thrombin generation assay, apixaban reduced endogenous thrombin potential, a measure of thrombin generation in human plasma.<br />Apixaban also demonstrates anti-FXa activity as evident by reduction in Factor Xa enzyme activity in multiple commercial anti-FXa kits, however results differ across kits. Data from clinical trials are only available for the Rotachrom&reg; Heparin chromogenic assay. Anti-FXa activity exhibits a close direct linear relationship withapixaban plasma concentration, reaching maximum values at the time of apixaban peak plasma concentrations. The relationship between apixaban plasma concentration and anti-FXa activity is approximately linear over a wide dose range of apixaban.<br />Table 3 below shows the predicted steady state exposure and anti-Factor Xa activity for each indication. In patients taking apixaban for the prevention of VTE following hip or knee replacement surgery, the results demonstrate a less than 1.6-fold fluctuation in peak-to-trough levels. In non-valvular atrial fibrillation patients taking apixaban for the prevention of stroke and systemic embolism, the results demonstrate a less than 1.7-fold fluctuation in peak-to-trough levels. In patients taking apixaban for the treatment of DVT and PE or prevention of recurrent DVT and PE, the results demonstrate a less than 2.2-fold fluctuation in peak-to-trough levels.</p><table border="1" cellspacing="1" cellpadding="0" style="width:693px"><tbody><tr><td colspan="5"><p>Table 3: Predicted Apixaban Steady-state Exposure and Anti-Xa Activity</p></td></tr><tr><td>&nbsp;</td><td><p>Apix.<br />Cmax (ng/mL)</p></td><td><p>Apix.<br />Cmin (ng/mL)</p></td><td><p>Apix. Anti-Xa Activity Max (IU/mL)</p></td><td><p>Apix. Anti-Xa Activity Min (IU/mL)</p></td></tr><tr><td>&nbsp;</td><td colspan="4"><p>Median [5th, 95th Percentile]</p></td></tr><tr><td colspan="5"><p>Prevention of VTE: elective hip or knee replacement surgery</p></td></tr><tr><td><p>2.5 mg twice daily</p></td><td><p>77 [41, 146]</p></td><td><p>51 [23, 109]</p></td><td><p>1.3 [0.67, 2.4]</p></td><td><p>0.84 [0.37, 1.8]</p></td></tr><tr><td colspan="5"><p>Prevention of stroke and systemic embolism: NVAF</p></td></tr><tr><td><p>2.5 mg twice daily*</p></td><td><p>123 [69, 221]</p></td><td><p>79 [34, 162]</p></td><td><p>1.8 [1.0, 3.3]</p></td><td><p>1.2 [0.51, 2.4]</p></td></tr><tr><td><p>5 mg twice daily</p></td><td><p>171 [91, 321]</p></td><td><p>103 [41, 230]</p></td><td><p>2.6 [1.4, 4.8]</p></td><td><p>1.5 [0.61, 3.4]</p></td></tr><tr><td colspan="5"><p>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</p></td></tr><tr><td><p>2.5 mg twice daily</p></td><td><p>67 [30, 153]</p></td><td><p>32 [11, 90]</p></td><td><p>1.0 [0.46, 2.5]</p></td><td><p>0.49 [0.17, 1.4]</p></td></tr><tr><td><p>5 mg twice daily</p></td><td><p>132 [59, 302]</p></td><td><p>63 [22, 177]</p></td><td><p>2.1 [0.91, 5.2]</p></td><td><p>1.0 [0.33, 2.9]</p></td></tr><tr><td><p>10 mg twice daily</p></td><td><p>251 [111, 572]</p></td><td><p>120 [41, 335]</p></td><td><p>4.2 [1.8, 10.8]</p></td><td><p>1.9 [0.64, 5.8]</p></td></tr></tbody></table><p>*Dose adjusted population based on 2 of 3 dose reduction criteria in the ARISTOTLE study.</p><p><br />Although treatment with apixaban does not require routine monitoring of exposure, a calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations where knowledge of apixaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery.<br /><strong>Clinical efficacy and safety</strong><br />Prevention of VTE (VTEp): elective hip or knee replacement surgery<br />The apixaban clinical program was designed to demonstrate the efficacy and safety of apixaban for the prevention of VTE in a broad range of adult patients undergoing elective hip or knee replacement. A total of 8,464 patients were randomized in two pivotal, double-blind, multi- national studies, comparing apixaban 2.5 mg given orally twice daily (4,236 patients) or enoxaparin 40 mg once daily (4,228 patients). Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight (&le; 60 kg), 1,495 patients (743 in the apixaban group) with BMI &ge; 33 kg/m2, and 415 patients (203 in theapixaban group) with moderate renal impairment.</p><p>The ADVANCE-3 study included 5,407 patients undergoing elective hip replacement, and the ADVANCE-2 study included 3,057 patients undergoing elective knee replacement. Subjects received either apixaban 2.5 mg given orally twice daily (po bid) or enoxaparin 40 mg administered subcutaneously once daily (sc od). The first dose of apixaban was given 12 to 24 hours post-surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. Both apixaban and enoxaparin were given for 32-38 days in the ADVANCE-3 study and for 10-14 days in the ADVANCE-2 study</p><p>Based on patient medical history in the studied population of ADVANCE-3 and ADVANCE-2 (8,464 patients), 46% had hypertension, 10% had hyperlipidemia, 9% had diabetes, and 8% had coronary artery disease.<br />Apixaban demonstrated a statistically superior reduction in the primary endpoint, a composite of all VTE/all cause death, and in the Major VTE endpoint, a composite of proximal DVT, non- fatal PE, and VTE-related death, compared to enoxaparin in both elective hip or knee replacement surgery (see Table 4).</p><p><strong>Table 4: Efficacy Results from Pivotal Phase III Studies</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:618px"><tbody><tr><td><p>Study</p></td><td colspan="3"><p>ADVANCE-3 (hip)</p></td><td colspan="3"><p>ADVANCE-2 (knee)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Study treatment<br />Dose</p></td><td><p>Apixaban<br />2.5mg po</p></td><td><p>Enoxaparin<br />40mg sc once</p></td><td><p>p-value</p></td><td><p>Apixaban<br />2.5mg po</p></td><td><p>Enoxaparin<br />40mg sc</p></td><td><p>p-value</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Duration of treatment</p></td><td><p>twice daily<br />35 &plusmn; 3 d</p></td><td><p>daily<br />35 &plusmn; 3 d</p></td><td>&nbsp;</td><td><p>twice daily<br />12 &plusmn; 2 d</p></td><td><p>once daily<br />12 &plusmn; 2 d</p></td><td>&nbsp;</td><td><p>&nbsp;</p></td></tr><tr><td colspan="7"><p>Total VTE/all-cause death</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Number of events/subjects Event Rate</p></td><td><p>27/1,949</p><p>1.39%</p></td><td><p>74/1,917</p><p>3.86%</p></td><td rowspan="2"><p>0.0001</p></td><td><p>147/976</p><p>15.06%</p></td><td><p>243/997</p><p>24.37%</p></td><td rowspan="2"><p>&lt;0.0001</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Relative Risk 95% CI</p></td><td><p>0.36</p><p>(0.22, 0.54)</p></td><td>&nbsp;</td><td><p>0.62</p><p>(0.51, 0.74)</p></td><td>&nbsp;</td><td><p>&nbsp;</p></td></tr><tr><td colspan="7"><p>Major VTE</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Number events/subjects Event Rate</p></td><td><p>10/2,199</p><p>0.45%</p></td><td><p>25/2,195</p><p>1.14%</p></td><td rowspan="2"><p>0.0107</p></td><td><p>13/1,195</p><p>1.09%</p></td><td><p>26/1,199</p><p>2.17%</p></td><td rowspan="2"><p>0.0373</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p>Relative Risk 95% CI</p></td><td rowspan="2"><p>0.40<br />(0.15, 0.80)</p></td><td rowspan="2">&nbsp;</td><td rowspan="2"><p>0.50</p><p>(0.26, 0.97)</p></td><td rowspan="2">&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td><p>&nbsp;</p></td></tr></tbody></table><p>The safety endpoints of major bleeding, the composite of major and clinically relevant non-major (CRNM) bleeding, and all bleeding showed similar rates for patients treated with apixaban 2.5 mg compared with enoxaparin 40 mg (see Table 5). All the bleeding criteria included surgical site bleeding.<br /><strong>Table 5: Bleeding Results from Pivotal Phase III Studies*</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:671px"><tbody><tr><td>&nbsp;</td><td colspan="2"><p>ADVANCE-3</p></td><td colspan="2"><p>ADVANCE-2</p></td></tr><tr><td>&nbsp;</td><td><p>Apixaban 2.5mg po twice daily 35 &plusmn; 3d</p></td><td><p>Enoxaparin 40mg sc once daily 35 &plusmn; 3d</p></td><td><p>Apixaban 2.5mg po twice daily 12 &plusmn; 2d</p></td><td><p>Enoxaparin 40mg sc once daily 12 &plusmn; 2d</p></td></tr><tr><td><p>All treated</p></td><td><p>n = 2,673</p></td><td><p>n = 2,659</p></td><td><p>n = 1,501</p></td><td><p>n = 1,508</p></td></tr><tr><td colspan="5"><p>Treatment Period 1</p></td></tr><tr><td><p>Major</p></td><td><p>22 (0.8%)</p></td><td><p>18 (0.7%)</p></td><td><p>9 (0.6%)</p></td><td><p>14 (0.9%)</p></td></tr><tr><td><p>Fatal</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Major + CRNM</p></td><td><p>129 (4.8%)</p></td><td><p>134 (5.0%)</p></td><td><p>53 (3.5%)</p></td><td><p>72 (4.8%)</p></td></tr><tr><td><p>All</p></td><td><p>313 (11.7%)</p></td><td><p>334 (12.6%)</p></td><td><p>104 (6.9%)</p></td><td><p>126 (8.4%)</p></td></tr><tr><td colspan="5"><p>Post-surgery treatment period 2</p></td></tr><tr><td><p>Major</p></td><td><p>9 (0.3%)</p></td><td><p>11 (0.4%)</p></td><td><p>4 (0.3%)</p></td><td><p>9 (0.6%)</p></td></tr><tr><td><p>Fatal</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr><tr><td><p>Major + CRNM</p></td><td><p>96 (3.6%)</p></td><td><p>115 (4.3%)</p></td><td><p>41 (2.7%)</p></td><td><p>56 (3.7%)</p></td></tr><tr><td><p>All</p></td><td><p>261 (9.8%)</p></td><td><p>293 (11.0%)</p></td><td><p>89 (5.9%)</p></td><td><p>103 (6.8%)</p></td></tr></tbody></table><p>*All the bleeding criteria included surgical site bleeding<br />1 Includes events occurring after first dose of enoxaparin (pre-surgery)<br />2 Includes events occurring after first dose of apixaban (post-surgery)<br />The overall incidences of adverse reactions of bleeding, anemia and abnormalities of transaminases (e.g., ALT levels) were numerically lower in patients on apixaban compared to enoxaparin in the phase II and phase III studies in elective hip and knee replacement surgery.<br />In the knee replacement surgery study during the intended treatment period, in the apixaban arm 4 cases of PE were diagnosed against no cases in the enoxaparin arm. No explanation can be given to this higher number of PE.<br />Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)<br />A total of 23,799 patients were randomised in the clinical program (ARISTOTLE: apixaban versus warfarin, AVERROES: apixaban versus ASA) including 11,927 randomised to apixaban. The program was designed to demonstrate the efficacy and safety of apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and one or more additional risk factors, such as:<br />&bull;prior stroke or transient ischaemic attack (TIA)<br />&bull;age &ge; 75 years<br />&bull;hypertension<br />&bull;diabetes mellitus<br />&bull;symptomatic heart failure (NYHA Class &ge; II)<br /><strong>ARISTOTLE STUDY</strong><br />In the ARISTOTLE study a total of 18,201 patients were randomised to double-blind treatment with apixaban 5mg twice daily (or 2.5 mg twice daily in selected patients [4.7%], see section 4.2) or warfarin (target INR range2.0-3.0), patients were exposed to study drug for a mean of 20 months. The mean age was 69.1 years, the meanCHADS2 score was 2.1 and 18.9% of patients had prior stroke or TIA.<br />In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke(haemorrhagic or ischaemic) and systemic embolism (see Table 6) compared with warfarin.</p><p><strong>Table 6: Efficacy Outcomes in Patients with Atrial Fibrillation in the ARISTOTLE Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:735px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban N=9,120<br />n (%/yr)</p></td><td><p>Warfarin N=9,081<br />n (%/yr)</p></td><td><p>Hazard Ratio (95% CI)</p></td><td><p>p-value</p></td></tr><tr><td><p>Stroke or systemic embolism</p></td><td><p>212 (1.27)</p></td><td><p>265 (1.60)</p></td><td><p>0.79 (0.66, 0.95)</p></td><td><p>0.0114</p></td></tr><tr><td><p>Stroke</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Ischaemic or unspecified</p></td><td><p>162 (0.97)</p></td><td><p>175 (1.05)</p></td><td><p>0.92 (0.74, 1.13)</p></td><td>&nbsp;</td></tr><tr><td><p>Hemorrhagic</p></td><td><p>40 (0.24)</p></td><td><p>78 (0.47)</p></td><td><p>0.51 (0.35, 0.75)</p></td><td>&nbsp;</td></tr><tr><td><p>Systemic embolism</p></td><td><p>15 (0.09)</p></td><td><p>17 (0.10)</p></td><td><p>0.87 (0.44, 1.75)</p></td><td>&nbsp;</td></tr></tbody></table><p>For patients randomised to warfarin, the median percentage of time in therapeutic range (TTR) (INR 2-3) was 66%.</p><p>Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40).</p><p>Key secondary endpoints of major bleeding and all cause death was tested in a pre-specified hierarchical testing strategy to control the overall type 1 error in the trial.</p><p>Statistically significant superiority was also achieved in the key secondary endpoints of both major bleeding and all-cause death (see Table 7). With improving monitoring of INR the observed benefits of apixaban compared to warfarin regarding all cause death diminish.</p><p><strong>Table 7: Secondary Endpoints in Patients with Atrial Fibrillation in the ARISTOTLE Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban N = 9,088<br />n (%/year)</p></td><td><p>Warfarin N = 9,052<br />n (%/year)</p></td><td><p>Hazard Ratio (95% CI)</p></td><td><p>p-value</p></td></tr><tr><td colspan="5"><p>Bleeding Outcomes</p></td></tr><tr><td><p>Major*</p></td><td><p>327 (2.13)</p></td><td><p>462 (3.09)</p></td><td><p>0.69 (0.60, 0.80)</p></td><td><p>&lt; 0.0001</p></td></tr><tr><td><p>Fatal</p></td><td><p>10 (0.06)</p></td><td><p>37 (0.24)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Intracranial</p></td><td><p>52 (0.33)</p></td><td><p>122 (0.80)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Major + CRNM</p></td><td><p>613 (4.07)</p></td><td><p>877 (6.01)</p></td><td><p>0.68 (0.61, 0.75)</p></td><td><p>&lt; 0.0001</p></td></tr><tr><td><p>All</p></td><td><p>2356 (18.1)</p></td><td><p>3060 (25.8)</p></td><td><p>0.71 (0.68, 0.75)</p></td><td><p>&lt; 0.0001</p></td></tr><tr><td colspan="5"><p>Other Endpoints</p></td></tr><tr><td><p>All-cause death</p></td><td><p>603 (3.52)</p></td><td><p>669 (3.94)</p></td><td><p>0.89 (0.80, 1.00)</p></td><td><p>0.0465</p></td></tr><tr><td><p>Myocardial infarction</p></td><td><p>90 (0.53)</p></td><td><p>102 (0.61)</p></td><td><p>0.88 (0.66, 1.17)</p></td><td>&nbsp;</td></tr></tbody></table><p>*Major bleeding defined per International Society on Thrombosis and Haemostasis (ISTH) criteria.<br />The overall discontinuation rate due to adverse reactions was 1.8% for apixaban and 2.6% for warfarin in the ARISTOTLE study.<br />The efficacy results for prespecified subgroups, including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the primary efficacy results for the overall population studied in the trial.<br />The incidence of ISTH major gastrointestinal bleeds (including upper GI, lower GI, and rectal bleeding) was 0.76%/year with apixaban and 0.86%/year with warfarin.<br />The major bleeding results for prespecified subgroups including CHADS2 score, age, body weight, gender, status of renal function, prior stroke or TIA and diabetes were consistent with the results for the overall population studied in the trial.<br /><strong>AVERROES STUDY</strong><br />In the AVERROES study a total of 5,598 patients considered to be unsuitable for VKA by the investigators were randomized to treatment with apixaban 5 mg twice daily (or 2.5 mg twice daily in selected patients [6.4%], see section 4.2) or ASA. ASA was given at a once daily dose of 81 mg (64%), 162 (26.9%), 243 (2.1%), or 324 mg (6.6%) at the discretion of the investigator. Patients were exposed to study drug for a mean of 14 months. The mean age was 69.9 years, the mean CHADS2 score was 2.0 and 13.6% of patients had prior stroke or TIA.<br />Common reasons for unsuitability for VKA therapy in the AVERROES study included unable/unlikely to obtain INRs at requested intervals (42.6%), patient refused treatment with VKA (37.4%), CHADS2 score = 1 and physician did not recommend VKA (21.3%), patient could not be relied on to adhere to VKA medicinal product instruction (15.0%), anddifficulty/expected difficulty in contacting patient in case of urgent dose change (11.7%).<br />AVERROES was stopped early based on a recommendation by the independent Data Monitoring Committee due to clear evidence of reduction of stroke and systemic embolism with an acceptable safety profile.<br />The overall discontinuation rate due to adverse reactions was 1.5% for apixaban and 1.3% for ASA in the AVERROES study.<br />In the study, apixaban achieved statistically significant superiority in the primary endpoint of prevention of stroke (haemorrhagic, ischaemic or unspecified) or systemic embolism (see Table 8)compared to ASA.</p><p><strong>Table 8: Key Efficacy Outcomes in Patients with Atrial Fibrillation in the AVERROES Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban N = 2,807<br />n (%/year)</p></td><td><p>ASA<br />N = 2,791<br />n (%/year)</p></td><td><p>Hazard Ratio (95% CI)</p></td><td><p>p-value</p></td></tr><tr><td><p>Stroke or systemic embolism*</p></td><td><p>51 (1.62)</p></td><td><p>113 (3.63)</p></td><td><p>0.45 (0.32, 0.62)</p></td><td><p>&lt; 0.0001</p></td></tr><tr><td><p>Stroke</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Ischaemic or unspecified</p></td><td><p>43 (1.37)</p></td><td><p>97 (3.11)</p></td><td><p>0.44 (0.31, 0.63)</p></td><td>&nbsp;</td></tr><tr><td><p>Haemorrhagic</p></td><td><p>6 (0.19)</p></td><td><p>9 (0.28)</p></td><td><p>0.67 (0.24, 1.88)</p></td><td>&nbsp;</td></tr><tr><td><p>Systemic embolism</p></td><td><p>2 (0.06)</p></td><td><p>13 (0.41)</p></td><td><p>0.15 (0.03, 0.68)</p></td><td>&nbsp;</td></tr><tr><td><p>Stroke, systemic embolism, MI,<br />or vascular death*&dagger;</p></td><td><p>132 (4.21)</p></td><td><p>197 (6.35)</p></td><td><p>0.66 (0.53, 0.83)</p></td><td><p>0.003</p></td></tr><tr><td><p>Myocardial infarction</p></td><td><p>24 (0.76)</p></td><td><p>28 (0.89)</p></td><td><p>0.86 (0.50, 1.48)</p></td><td>&nbsp;</td></tr><tr><td><p>Vascular Death</p></td><td><p>84 (2.65)</p></td><td><p>96 (3.03)</p></td><td><p>0.87 (0.65, 1.17)</p></td><td>&nbsp;</td></tr><tr><td><p>All-cause death&dagger;</p></td><td><p>111 (3.51)</p></td><td><p>140 (4.42)</p></td><td><p>0.79 (0.62, 1.02)</p></td><td><p>0.068</p></td></tr></tbody></table><p>*Assessed by sequential testing strategy designed to control the overall type I error in the trial.<br />&dagger; Secondary endpoint.<br />There was no statistically significant difference in the incidence of major bleeding between apixaban and ASA (see Table 9).<br /><strong>Table 9: Bleeding Events in Patients with Atrial Fibrillation in the AVERROES Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban N = 2,798 n(%/year)</p></td><td><p>ASA<br />N = 2,791<br />n (%/year)</p></td><td><p>ASA N = 2,780<br />n (%/year)</p></td><td><p>p-value</p></td></tr><tr><td><p>Major*</p></td><td><p>45 (1.41)</p></td><td><p>29 (0.92)</p></td><td><p>1.54 (0.96, 2.45)</p></td><td><p>0.0716</p></td></tr><tr><td><p>Fatal, n</p></td><td><p>5 (0.16)</p></td><td><p>5 (0.16)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Intracranial, n</p></td><td><p>11 (0.34)</p></td><td><p>11 (0.35)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Major + CRNM&dagger;</p></td><td><p>140 (4.46)</p></td><td><p>101 (3.24)</p></td><td><p>1.38 (1.07, 1.78)</p></td><td><p>0.0144</p></td></tr><tr><td><p>All</p></td><td><p>325 (10.85)</p></td><td><p>250 (8.32)</p></td><td><p>1.30 (1.10, 1.53)</p></td><td><p>0.0017</p></td></tr></tbody></table><p>*Major bleeding defined per International Society on Thrombosis ad Haemostasis (ISTH) criteria.<br />&dagger; Clinically Relevant Non-Major<br />Patients undergoing cardioversion<br />EMANATE, an open-label, multi-center study, enrolled 1500 patients who were either oral anticoagulant na&iuml;ve or pre-treated less than 48 hours, and scheduled for cardioversion for NVAF. Patients were randomized 1:1 to apixaban or to heparin and/or VKA for the prevention of cardiovascular events. Electrical and/or pharmacologic cardioversion was conducted after at least 5 doses of 5 mg twice daily apixaban (or 2.5 mg twice daily in selected patients (see section 4.2)) or at least 2 hours after a 10 mg loading dose (or a 5 mg loading dose in selected patients(see section 4.2)) if earlier cardioversion was required. In the apixaban group, 342 patients received a loading dose (331 patients received the 10 mg dose and 11 patients received the 5 mg dose).<br />There were no strokes (0%) in the apixaban group (n= 753) and 6 (0.80%) strokes in the heparin and/or VKA group (n = 747; RR 0.00, 95% CI 0.00, 0.64). All-cause death occurred in 2 patients (0.27%) in the apixaban group and 1 patient (0.13%) in the heparin and/or VKA group. No systemic embolism events were reported.<br />Major bleeding and CRNM bleeding events occurred in 3 (0.41%) and 11 (1.50%) patients, respectively, in the apixaban group, compared to 6 (0.83%) and 13 (1.80%) patients in the heparin and/or VKA group.<br />This exploratory study showed comparable efficacy and safety between apixaban and heparin and/or VKA treatment groups in the setting of cardioversion.</p><p><strong>Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt)</strong><br />The clinical program (AMPLIFY: apixaban versus enoxaparin/warfarin, AMPLIFY-EXT: apixaban versus placebo) was designed to demonstrate the efficacy and safety of apixaban for the treatment of DVT and/or PE (AMPLIFY), and extended therapy for the prevention of recurrent DVT and/or PE following 6 to 12 months of anticoagulant treatment for DVT and/or PE (AMPLIFY-EXT). Both studies were randomised, parallel-group, double-blind, multinational trials in patients with symptomatic proximal DVT or symptomatic PE. All the key safety and efficacy endpoints were adjudicated by an independent blinded committee.<br /><strong>AMPLIFY STUDY</strong><br />In the AMPLIFY study a total of 5,395 patients were randomised to treatment with apixaban 10 mg twice daily orally for 7 days followed by apixaban 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR&ge; 2) and warfarin (target INR range 2.0-3.0) orally for 6 months.<br />The mean age was 56.9 years and 89.8% of randomised patients had unprovoked VTE events.<br />For patients randomised to warfarin, the mean percentage of time in therapeutic range (INR 2.0- 3.0) was 60.9. Apixaban showed a reduction in recurrent symptomatic VTE or VTE- related death across the different levels of center TTR; within the highest quartile of TTR according to center, the relative risk for apixaban vs enoxaparin/warfarin was 0.79 (95% CI, 0.39, 1.61).</p><p>In the study, apixaban was shown to be non-inferior to enoxaparin/warfarin in the combined primary endpoint of adjudicated recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related death (see Table 10).</p><p><strong>Table 10: Efficacy Results in the AMPLIFY Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:438px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban N=2,609 n (%)</p></td><td><p>Enoxaparin/Warfarin N=2,635 n (%)</p></td><td><p>Relative Risk (95% CI)</p></td></tr><tr><td><p>VTE or VTE-related<br />death</p></td><td><p>59 (2.3)</p></td><td><p>71 (2.7)</p></td><td><p>0.84 (0.60, 1.18)*</p></td></tr><tr><td><p>DVT</p></td><td><p>20 (0.7)</p></td><td><p>33 (1.2)</p></td><td>&nbsp;</td></tr><tr><td><p>PE</p></td><td><p>27 (1.0)</p></td><td><p>23 (0.9)</p></td><td>&nbsp;</td></tr><tr><td><p>VTE-related death</p></td><td><p>12 (0.4)</p></td><td><p>15 (0.6)</p></td><td>&nbsp;</td></tr><tr><td><p>VTE or all-cause death</p></td><td><p>84 (3.2)</p></td><td><p>104 (4.0)</p></td><td><p>0.82 (0.61, 1.08)</p></td></tr><tr><td><p>VTE or CV-related death</p></td><td><p>61 (2.3)</p></td><td><p>77 (2.9)</p></td><td><p>0.80 (0.57, 1.11)</p></td></tr><tr><td><p>VTE, VTE-related</p></td><td><p>73 (2.8)</p></td><td><p>118 (4.5)</p></td><td><p>0.62 (0.47, 0.83)</p></td></tr><tr><td><p>death, or major bleeding</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*Noninferior compared to enoxaparin/warfarin (p-value &lt;0.0001)<br />Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)]. Efficacy across subgroups, including age, gender, body mass index (BMI), renal function, extent of index PE, location of DVT thrombus, and prior parenteral heparin use was generally consistent.<br />The primary safety endpoint was major bleeding. In the study, apixaban was statistically superior to enoxaparin/warfarin in the primary safety endpoint [Relative Risk 0.31, 95% confidence interval (0.17, 0.55), P-value &lt;0.0001] (see Table 11).<br /><strong>Table 11: Bleeding Results in the AMPLIFY Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:438px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban N=2,676 n (%)</p></td><td><p>Enoxaparin/ Warfarin N=2,689 n (%)</p></td><td><p>Relative Risk (95% CI)</p></td></tr><tr><td><p>Major</p></td><td><p>15 (0.6)</p></td><td><p>49 (1.8)</p></td><td><p>0.31 (0.17, 0.55)</p></td></tr><tr><td><p>Major + CRNM</p></td><td><p>115 (4.3)</p></td><td><p>261 (9.7)</p></td><td><p>0.44 (0.36, 0.55)</p></td></tr><tr><td><p>Minor</p></td><td><p>313 (11.7)</p></td><td><p>505 (18.8)</p></td><td><p>0.62 (0.54, 0.70)</p></td></tr><tr><td><p>All</p></td><td><p>402 (15.0)</p></td><td><p>676 (25.1)</p></td><td><p>0.59 (0.53, 0.66)</p></td></tr></tbody></table><p>The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban<br />group as compared to the enoxaparin/warfarin group. Adjudicated ISTH major gastrointestinal bleeding occurred in 6 (0.2%) apixaban-treated patients and 17 (0.6%) enoxaparin/warfarin-treated patients.</p><p><strong>AMPLIFY-EXT STUDY</strong><br />In the AMPLIFY-EXT study a total of 2,482 patients were randomised to treatment with apixaban 2.5 mg twice daily orally, apixaban 5 mg twice daily orally, or placebo for 12 months after completing 6 to 12 months of initial anticoagulant treatment. Of these, 836 patients (33.7%) participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.<br />The mean age was 56.7 years and 91.7% of randomised patients had unprovoked VTE events.<br />In the study, both doses of apixaban were statistically superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE) or all-cause death (see Table 12).<br /><strong>Table 12: Efficacy Results in the AMPLIFY-EXT Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td>&nbsp;</td><td><p>Apixaban</p></td><td><p>Apixaban</p></td><td><p>Placebo</p></td><td colspan="2"><p>Relative Risk (95% CI)</p></td></tr><tr><td>&nbsp;</td><td><p>2.5 mg<br />(N=840)</p></td><td><p>5.0 mg<br />(N=813)</p></td><td><p>(N=829)</p></td><td><p>Apixaban 2.5mg<br />vs. Placebo</p></td><td><p>Apix 5.0 mg vs. Placebo</p></td></tr><tr><td>&nbsp;</td><td colspan="3"><p>n (%)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Recurrent VTE or all-cause death</p></td><td><p>19 (2.3)</p></td><td><p>14 (1.7)</p></td><td><p>77 (9.3)</p></td><td><p>0.24<br />(0.15, 0.40)&yen;</p></td><td><p>0.19<br />(0.11, 0.33)&yen;</p></td></tr><tr><td><p>DVT*</p></td><td><p>6 (0.7)</p></td><td><p>7 (0.9)</p></td><td><p>53 (6.4)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>PE*</p></td><td><p>7 (0.8)</p></td><td><p>4 (0.5)</p></td><td><p>13 (1.6)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>All-cause death</p></td><td><p>6 (0.7)</p></td><td><p>3 (0.4)</p></td><td><p>11 (1.3)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Recurrent VTE or VTE-related<br />death</p></td><td><p>14 (1.7)</p></td><td><p>14 (1.7)</p></td><td><p>73 (8.8)</p></td><td><p>0.19<br />(0.11, 0.33)</p></td><td><p>0.20<br />(0.11, 0.34)</p></td></tr><tr><td><p>Recurrent VTE<br />Or CV-related death</p></td><td><p>14 (1.7)</p></td><td><p>14 (1.7)</p></td><td><p>76 (9.2)</p></td><td><p>0.18<br />(0.10, 0.32)</p></td><td><p>0.19<br />(0.11, 0.33)</p></td></tr><tr><td><p>Nonfatal DVT&dagger;</p></td><td><p>6 (0.7)</p></td><td><p>8 (1.0)</p></td><td><p>53 (6.4)</p></td><td><p>0.11<br />(0.05, 0.26)</p></td><td><p>0.15<br />(0.07, 0.32)</p></td></tr><tr><td><p>Nonfatal PE&dagger;</p></td><td><p>8 (1.0)</p></td><td><p>4 (0.5)</p></td><td><p>15 (1.8)</p></td><td><p>0.51<br />(0.22, 1.21)</p></td><td><p>0.27<br />(0.09, 0.80)</p></td></tr><tr><td><p>VTE-related<br />death</p></td><td><p>2 (0.2)</p></td><td><p>3 (0.4)</p></td><td><p>7 (0.8)</p></td><td><p>0.28<br />(0.06, 1.37)</p></td><td><p>0.45<br />(0.12, 1.71)</p></td></tr></tbody></table><p>&yen;p-value &lt; 0.0001</p><p>*For patients with more than one event contributing to the composite endpoint, only the first event was reported(eg, if a subject experienced both a DVT and then a PE, only the DVT was reported)<br />&dagger; Individual subjects could experience more than one event and be represented in both classifications<br />Apixaban efficacy for prevention of a recurrence of a VTE was maintained across subgroups, including age, gender, BMI, and renal function.<br />The primary safety endpoint was major bleeding during the treatment period. In the study, the incidence in major bleeding for both apixaban doses was not statistically different from placebo. There was no statistically significant difference in the incidence of major + CRNM, minor, and all bleeding between the apixaban 2.5 mg twice daily and placebo treatment groups (see Table 13).<br /><strong>Table 13: Bleeding Results in the AMPLIFY-EXT Study</strong></p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td rowspan="2">&nbsp;</td><td><p>Apixaban</p></td><td><p>Apixaban</p></td><td><p>Placebo</p></td><td colspan="2"><p>Relative Risk (95% CI)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2"><p>2.5 mg<br />(N=840)</p></td><td rowspan="2"><p>5.0 mg<br />(N=811)</p><p>n (%)</p></td><td rowspan="2"><p>(N=826)</p></td><td rowspan="2"><p>Apixaban 2.5mg<br />vs. Placebo</p></td><td rowspan="2"><p>Apix 5.0 mg vs. Placebo</p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>&nbsp;</p></td></tr><tr><td><p>Major</p></td><td><p>2 (0.2)</p></td><td><p>1 (0.1)</p></td><td><p>4 (0.5)</p></td><td><p>0.49<br />(0.09, 2.64)</p></td><td><p>0.25<br />(0.03, 2.24)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Major + CRNM</p></td><td><p>27 (3.2)</p></td><td><p>35 (4.3)</p></td><td><p>22 (2.7)</p></td><td><p>1.20<br />(0.69, 2.10)</p></td><td><p>1.62<br />(0.96, 2.73)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Minor</p></td><td><p>75 (8.9)</p></td><td><p>98 (12.1)</p></td><td><p>58 (7.0)</p></td><td><p>1.26<br />(0.91, 1.75)</p></td><td><p>1.70<br />(1.25, 2.31)</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>All</p></td><td><p>94 (11.2)</p></td><td><p>121 (14.9)</p></td><td><p>74 (9.0)</p></td><td><p>1.24<br />(0.93, 1.65)</p></td><td><p>1.65<br />(1.26, 2.16)</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>Adjudicated ISTH major gastrointestinal bleeding occurred in 1 (0.1%) apixaban-treated patient at the 5 mg twice daily dose, no patients at the 2.5 mg twice daily dose, and 1 (0.1%) placebo- treated patient.<br /><strong>Pediatric population</strong><br />The European Medicines Agency has deferred the obligation to submit the results of studies with Apixaban in one or more subsets of the pediatric population in venous and arterial embolism and thrombosis (see section 4.2 for information on pediatric use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Apixaban is rapidly absorbed with maximum concentrations (Cmax) appearing 3 to 4 hours after tablet intake. Intake with food does not affect apixaban AUC or Cmax at the 10 mg dose. Apixaban can be taken with or without food. Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg. At doses &ge; 25 mg apixaban displays dissolution limited absorption with decreased bioavailability. Apixaban exposure parameters exhibit low to moderate variability reflected by a within-subject and inter-subject variability of ~20% CV and ~30% CV, respectively. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of<br />water, exposure was comparable to exposure after oral administration of 2 whole 5 mg tablets. Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets with 30 g of apple puree, the Cmax and AUC were 21% and 16% lower, respectively, when compared to administration of 2 whole 5 mg tablets. The reduction in exposure is not considered clinically relevant.<br />Following administration of a crushed 5 mg apixaban tablet suspended in 60 mL of D5W and delivered via a nasogastric tube, exposure was similar to exposure seen in other clinical trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose.<br />Given the predictable, dose-proportional pharmacokinetic profile of apixaban, the bioavailability results from the conducted studies are applicable to lower apixaban doses</p><p>Distribution</p><p>Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 litres.</p><p>Biotransformation and elimination</p><p>Apixaban has multiple routes of elimination. Of the administered apixaban dose in humans, approximately 25% was recovered as metabolites, with the majority recovered in faeces. Renal excretion of apixaban accounts for approximately 27% of total clearance. Additional contributions from biliary and direct intestinal excretion were observed in clinical and nonclinical studies, respectively.<br />Apixaban has a total clearance of about 3.3 L/h and a half-life of approximately 12 hours.<br />O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation. Apixaban is metabolised mainly via CYP3A4/5 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. Unchanged apixaban is the major drug-related component in human plasma with no active circulating metabolites present. Apixaban is a substrate of transport proteins, P-gp and breast cancer resistance protein (BCRP).</p><p>Renal impairment</p><p>There was no impact of impaired renal function on peak concentration of apixaban. There was an increase in apixaban exposure correlated to decrease in renal function, as assessed via measured creatinine clearance. In individuals with mild (creatinine clearance 51-80 mL/min), moderate (creatinine clearance 30-50 mL/min) and severe (creatinine clearance 15-29 mL/min) renal impairment, apixaban plasma concentrations (AUC) were increased 16, 29, and 44% respectively, compared to individuals with normal creatinine clearance. Renal impairment had no evident effect on the relationship between apixaban plasma concentration and anti-FXa activity.<br />In subjects with end-stage renal disease (ESRD), the AUC of apixaban was increased by 36% when a single dose of apixaban 5 mg was administered immediately after haemodialysis, compared to that seen in subjects with normal renal function. Haemodialysis, started two hours after administration of<br />a single dose of apixaban 5 mg, decreased apixaban AUC by 14% in these ESRD subjects, corresponding to an apixaban dialysis clearance of 18 mL/min. Therefore, haemodialysis is unlikely to be an effective means of managing apixabanoverdose.</p><p>Hepatic impairment</p><p>In a study comparing 8 subjects with mild hepatic impairment, Child-Pugh A score 5 (n = 6) and score 6 (n = 2), and 8 subjects with moderate hepatic impairment, Child-Pugh B score 7 (n = 6) and score 8 (n = 2), to 16 healthy control subjects, the single-dose pharmacokinetics and pharmacodynamics of apixaban 5 mg were not altered in subjects with hepatic impairment. Changes in anti-Factor Xa activity and INR were comparable between subjects with mild to moderate hepatic impairment and healthy subjects.</p><p>Elderly</p><p>Elderly patients (above 65 years) exhibited higher plasma concentrations than younger patients, with meanAUC values being approximately 32% higher and no difference in Cmax</p><p>Gender</p><p>Exposure to apixaban was approximately 18% higher in females than in males</p><p>Ethnic origin and race</p><p>The results across phase I studies showed no discernible difference in apixaban pharmacokinetics between White/Caucasian, Asian and Black/African American subjects. Findings from a population pharmacokinetic analysis in patients who received apixaban were generally consistent with the phase I results</p><p>Body weight</p><p>Compared to apixaban exposure in subjects with body weight of 65 to 85 kg, body weight &gt; 120 kg was associated with approximately 30% lower exposure and body weight &lt; 50 kg was associated with approximately 30% higher exposure</p><p>Pharmacokinetic/pharmacodynamic relationship</p><p>The pharmacokinetic /pharmacodynamic (PK/PD) relationship between apixaban plasma concentration and several PD endpoints (anti-FXa activity, INR, PT, aPTT) has been evaluated after administration of a wide range of doses (0.5 &ndash; 50 mg). The relationship between apixaban plasma concentration and anti-Factor Xa activity was best described by a linear model. The PK/PD relationship observed in patients was consistent with that established in healthy subjects</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, fertility and embryo- foetal development and juvenile toxicity. The major observed effects in the repeated dose toxicity studies were those related to the pharmacodynamic action of apixaban on blood coagulation parameters. In the toxicity studies little to no increase of bleeding tendency was found. However, since this may be due to a lower sensitivity of the non-clinical species compared to humans, this result should be interpreted with caution when extrapolating to humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: Lactose monohydrate , Microcrystalline cellulose PH 101 , Croscarmellose sodium , Sodium lauryl sulfate , Purified water , Magnesium stearate. Coating material: Opadry II Pink 32K540068</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30˚C. Protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10&#39;s PVC/PVdC-Alu Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC) King Fahad road, Building 911- The First Round Riyadh, Saudi Arabia Tel: +966-11-4668193 Fax: +966-11-4668195 Email: info@sudairpharma.com Mailing: P.O. Box 19047 Riyadh, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>